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Abstract
Cancer cachexia (CC) is a devastating wasting syndrome characterized by marked weight
loss including skeletal muscle atrophy that affects approximately 80% of cancer patients. Current
therapeutic treatments including pharmacological and nutritional intervention are insufficient to
prevent or reverse it. Prior studies demonstrated lower muscle mass, impaired muscle function,
and mitochondrial health in the development of CC. Specifically, mitochondrial fusion protein,
Optic atrophy 1 (OPA1) which plays a significant role in skeletal muscle health, is suppressed in
the development of CC. Furthermore, most pre-clinical CC studies were mainly focused on males
although there are distinct phenotypical differences in skeletal muscle between males and
females. Therefore, these studies were set to investigate two independent research questions
(Chapter 3 & 4). The purpose of this dissertation project was to investigate skeletal muscle
alterations during the development of CC in female tumor-bearing mice (Chapter 3) and determine
the efficacy of OPA1 as a therapeutic target for cancer-induced muscle atrophy (Chapter 4). To
accomplish this research plan, I completed a series of studies using both cell culture and animal
models of CC. For the Chapter 3 experiments, 60 female mice were given either an IP injection
of PBS or Lewis Lung Carcinoma (LLC) injection and the tumors were allowed to grow for 1, 2, 3,
or 4-wk to assess the time course of cachectic development. We found a dichotomous effect on
tumor mass between 3- and 4-wk animals where approximately half of mice between the two
groups exhibited low tumor (LT) mass (<1.2 g) while the other half developed higher tumor (HT)
mass (>2 g). Furthermore, HT mice revealed greater protein degradation, impaired muscle
contractility, and mitochondrial degeneration. These alterations are relatively modest when
compared to male data from previous studies. For the Chapter 4 experiments, I utilized both
pharmacological (in vitro & in vivo) and genetic overexpression of OPA1 (OPA1 TG) in LLCconditioned media (LCM) and LLC-induced CC. 72 hours of LCM intervention induced smaller
myotubes, which was normalized by BGP-15 treatment and this effect appeared to be driven by

suppressed inflammatory cytokine and autophagic-lysosomal pathway (ALP) activity at the mRNA
level. 4-wk of LLC implantation was sufficient to induce cachectic phenotype while this effect was
normalized in OPA1 overexpression in tumor-bearing mice. In conclusion, my dissertation data
suggests both biological sex as an important variable and OPA1 as a novel therapeutic target for
cancer-induced muscle wasting.
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CHAPTER I: REVIEW OF LITERATURE

Seongkyun Lim & Nicholas P. Greene

A. INTRODUCTION
Cancer Cachexia (CC) results in an involuntary weight loss of lean body mass, which
leads to reduced mobility, quality of life, and increases mortality(1). Approximately one-quarter of
all cancer-related death is due to CC (2, 3). Nutritional intervention has not been successful and
overall, to date there are currently no effective treatments to reverse or prevent CC (4). Although
preclinical CC studies are limited to mimic the nature of human cancer, they have provided
potential therapeutic strategies to improve cancer outcomes (5-9). Most pre-clinical studies of CC
are mainly focused on males and cachectic signatures during the development of CC in females
are still lacking. Prior evidence indicates distinct biological sex differences in skeletal muscle
phenotype, and skeletal muscle responses in males and females to various myopathies are
distinct, including disuse-induced muscle atrophy (10, 11). Therefore, a critical need remains to
understand phenotypical and molecular alterations in the skeletal muscle across biological sex
during the development of CC.
Mitochondrial health and function have long been implicated with various human diseases
including CC (12-15). Impaired mitochondrial function and quality have been reported from
various clinical (16, 17) and preclinical CC studies (12, 18). Previous evidence from our laboratory
demonstrated mitochondrial degeneration including lower mitochondrial fusion protein content
precedes cancer-induced muscle wasting (12). However, it is unknown if early targeting of
mitochondrial fusion prevents cachectic phenotypes and improves cancer outcomes. Additional
supportive investigations on targeting mitochondrial fusion are needed to elucidate mitochondrial
regulations during the development of CC. The purpose of the current dissertation literature
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review is to discuss skeletal muscle alterations during the development of CC across biological
sex using preclinical animal models and the role of mitochondria in CC.

B. Cancer Cachexia

i.

Recent cancer statistics
Cancer has been a leading cause of death in many countries of the world, responsible for

approximately 10 million deaths in 2020 (19). Specifically, the World Health Organization (WHO)
has recently (2020) reported that cancer was the first or second leading cause of death before
the age of 70 years in 112 of 183 countries globally. Furthermore, the global cancer incidence
rate is expected to be increased by ~47% in 2040 (28.4 million cases) from 2020 (19.3 million
cases) (19). In addition, the majority of cancer patients experience many symptoms including
unintended weight loss, anorexia, and fatigue, which affect their mortality and quality of life (1).

ii.

Cancer Cachexia: Mechanism of Muscle Wasting
Cancer cachexia (CC), cancer-induced muscle loss, is a multifactorial syndrome

characterized by a progressive loss of skeletal muscle mass, which can affect up to 80% of cancer
patients depending on the type of cancer (2, 20). CC is clinically defined as 5% of bodyweight
loss over a 6-month period, or weight loss > 2% in individuals already showing depletion (body
mass index <20 kg/m2) or low skeletal muscle mass (sarcopenia) (3). CC is the primary cause of
death for 22-30% of cancer patients (2, 20), with incidence predicted to grow in years to come
(21). CC is often irreversible once weight loss begins to occur; therefore, using weight loss as
diagnostic criteria is therapeutically superlative, requiring the need to identify a pre-cachectic
signature both for diagnostic and prevention/mitigation purposes.
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All cancers can present with cachexia and common cancers such as those of the
pancreas, lung, and liver are responsible for approximately half of all cancer-related deaths
worldwide (22). Cancers more commonly associated with cachexia are often diagnosed at an
advanced stage (cachectic state) and have direct effects on digestion (23), at which point the
condition is mostly irreversible back to pre-cachectic state. Baseline assessments of pre-cachexia
(early stage of CC without marked weight loss; i.e., ≤5%) (3) or mass loss history are critical for
predicting CC trajectory (24). To predict if CC will occur in patients, there is a desperate need for
a defined pre-cachectic signature, which would allow for the development and implementation of
preventative therapeutic strategies to decrease the cancer-induced mortality rate.
Many clinical studies have taken place to identify characteristics of CC across several
diverse types of cancers in humans. However, results of clinical studies often show varying
outcomes compared to pre-clinical models. While pre-clinical models have consistently shown
that muscle proteolysis (breakdown process) occurs with CC, the results from clinical studies are
much more variable (25). One source of variation could be that in pre-clinical models of
experimental conditions such as tumor size are tightly controlled for, while in clinical studies the
progression of cancer is often not controlled for. Our group has recently reviewed common preclinical models of CC (26), notably, current efforts are ongoing to develop pre-clinical models of
CC to more accurately recapitulate human CC.

C. Pre-Clinical Rodent Models to Study Cancer Cachexia

i.

Pre-Clinical Rodent Models of Cancer Cachexia
Pre-clinical models are limited to perfectly mimic the heterogeneity of human cancer,

research findings from studies utilizing pre-clinical animal models of CC have provided potential
therapeutic strategies to improve cancer outcomes (5-9). There are two types of commonly used
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pre-clinical animal CC models including tumor allograft and genetically mutated CC models.
Tumor allograft-induced tumor-bearing mouse is mainly driven via subcutaneous tumor cell
injection into the flank of a mouse wherein the tumors grow relatively fast and develops a
cachectic phenotype within a few wks following the tumor injection in most cases (12, 27).
Currently, several tumor allograft rodent models to study CC have been used including Lewis
Lung Carcinoma (LLC; lung cancer model) (28), Colon-26 (C26; colorectal cancer model )(29),
MAC16 (colon cancer model) (30, 31), Yoshida AH-ascites (AH-130; hepatic cancer model) (32),
RXF (renal cancer model) (33), and Walker-256 (breast cancer model) (34). On the other hand,
one of the most widely used genetic (transgenic) CC animal models is Adenomatous Polyposis
Coli (ApcMin/+; colorectal cancer model) (35-37). Mutation of the ApcMin/+ gene represents a large
percentage of human colon cancer cases and genetic mutation of ApcMin/+ in rodents will
spontaneously develop intestinal adenomas and it has become an excellent pre-clinical model to
mimic human colorectal cancer (35-37). In addition, Talbert et al (38) recently introduced a new
genetically modified animal model of CC. in this study, they engineered a mouse model of
pancreatic ductal adenocarcinoma (PDA) via breeding KrasLSL-G12D/+, PTEN+/f mice to
Ptf1aER-Cre/+, PTEN+/f mice and this animal model is similar to PDA patients including
progressive loss of skeletal muscle and adipose mass as well as similar gene ontology in
response to tumor development.

Among different pre-clinal rodent CC models, this review will concentrate on the LLCinduced tumor-bearing mouse model in this current project. Lung cancer remains the leading
cause of cancer-related death in 2020 and one of the most commonly diagnosed cancers in
human (19). The LLC cell line was first developed in 1980 (28) and has been widely used since
the 1990s. Upon the LLC tumor allograft, it generally takes up to 4 wks to fully develop the tumor
sufficiently to induce cachectic phenotype (12, 27). At a 4-wk time point, the tumor sizes typically
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average ~2.5 grams (12, 27) which may limit direct application of these models to human cachexia
due to its large tumor size (~10% of body weight is attributable to tumor mass).

As a preventative purpose, understanding pre-cachectic signatures are imperative to
prevent cancer-induced muscle wasting and other cachectic phenotypes. However, clinical
cancer studies have not been successful to effectively investigate the pre-cachectic signatures.
Since most cancer patients are diagnosed with cancer when they are already experiencing
cachectic phenotypes such as weight loss, at which point is difficult to treat to reverse. One of the
benefits of using pre-clinal animal models is that researchers can observe physiological or
molecular changes during the initial stages of tumor development. Our laboratory has committed
to study pre-cachectic signatures utilizing pre-clinical animal models of CC, and we found some
novel evidence. We found that mitochondrial degeneration such as impaired ROS emission and
mitochondrial dynamics preceded cancer-induced cachectic phenotype in LLC tumor-bearing
male mice (12). However, studies investigating pre-cachectic signatures are still sparse, making
it difficult to develop therapeutic treatments to prevent cancer-induced muscle wasting during
early-stage cancer.

D. Sex Differences in Cancer Cachexia

i.

Phenotypical differences between sexes in various myopathies
Skeletal muscle mass takes up to 40% of total body mass and is maintained via a

homeostatic balance between protein synthesis and protein degradation, whereby an increase in
protein degradation to synthesis ratio results in muscle loss (39). Loss of muscle mass is closely
associated with various muscle pathologies(40) as well as lower quality of life (41) and higher
mortality (42, 43). Although muscle loss is a common symptom for many muscle pathologies
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including cancer (27), the mechanisms contributing to muscle wasting vary depending on the
types of pathologies. For example, muscle atrophy is associated with inflammatory action of the
tumor-host interactions in cancer (38, 44), while this interaction is absent during other pathologies
such as disuse-induced muscle wasting. In addition, recent evidence suggests there are distinct
phenotypical differences in development of muscle atrophy between males and females (45).
Females tend to rely more on oxidative metabolism and have greater relative content of type 1
(oxidative/slow-twitch) muscle fibers compared to males, who have more type 2 fibers (glycolytic/
fast-twitch) compared to females (46-48). Disuse-induced muscle atrophy extensively occurs in
type 1 oxidative muscle fibers, while inflammation-induced muscle wasting occurs preferentially
in type 2 glycolytic muscle fibers (12, 49, 50). Thus, females appear to be more vulnerable to
disuse-induced muscle wasting (51-53), while males are more sensitive to cancer-induced muscle
wasting (12, 49, 50). Nevertheless, the role of biological sex in different forms of muscle
pathologies including CC remains understudied. This relative dearth of information likely
contributes to the current lack in effective therapeutic strategies.

ii.

Sex differences in Cancer Cachexia
Biological sex has been recently reported as an important factor in terms of cancer

incidence and mortality (54). Although both male and female cancer patients exhibit cachexia, the
development of CC may differ between sexes (45). A recent study shows cancer incidence is
20% higher in males than females and the male-to-female incidence ratio was distinctly different
in many primary malignant tumor developments such as liver, bladder, oral cavity, esophageal,
and thyroid cancer in the US (55). The mortality rate in malignant cancers is ~30% higher in males
compared to females in various age groups (56, 57). Moreover, cancer-induced cachexia
generally occurs in 40-50% of female patients and 40-60% of male patients over 60 years of age
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(58, 59) and the overall prevalence of severe muscle loss criteria among cancer patients was
much higher in males (61%) than females (31%) (60). Although CC occurs in both male and
female populations, mechanisms that drive muscle loss differ between sexes (45, 61). Females
are less sensitive to inflammation-mediated activation of the ubiquitin-proteasome system and
subsequent muscle protein breakdown, common in CC, as compared to males (50, 62, 63). In
addition, the Carson group demonstrated while male Apcmin/+ mice exhibit a high IL-6 dependency
for cancer development, female mice demonstrate a relative IL-6 independency (15, 64).
Differences in the inflammation and protein breakdown pathways observed in prior works show
distinct variations in cancer-induced muscle degradation mechanisms that occur between sexes
in mice (45, 61). Although above-mentioned data indicate the biological sex difference in muscle
phenotype and inflammation-induced muscle pathologies, most pre-clinical studies of CC are
mainly focused on males. Therefore, more studies are needed to delineate the ambiguous roles
of biological sex during the development and progression of CC. Considering differences in CC
susceptibility by biological sex, explorations of mechanistic differences in CC between biological
sexes may provide valuable insight to therapeutic approaches to prevent or attenuate this
condition.

E. Skeletal Muscle Contractile Properties in Cancer Cachexia

i.

Muscle contractility & Extracellular Matrix (ECM)
In addition to muscle loss, reduced muscle strength is an important indicator of the survival

rate among patients with advanced cancer (65). One of the major features of skeletal muscle is
the ability to produce force and the intrinsic mechanism is controlled by contractile properties such
as fiber type, motor unit, ATPase activity, calcium homeostasis (14, 66), and neuromuscular
connection (67). However, prior evidence notes that multiple deficits in muscle contractility (force
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production and fatigability) and contractile properties have been identified in tumor-bearing
cachectic mice (68-70) and advanced cancer patients (65) as well as primary cells derived from
cancer patients (71). Notably, increased muscle fatigability was present in weight stable ApcMin/+
mice (69), suggesting increased muscle fatigability in pre-cachexia may serve as an early
functional marker for CC. The capacity to produce muscle force has become an excellent indicator
of survival rate among patients or rodents with advanced cancer as these patients and animals
often show diminished force production and elevated fatigability (65, 69, 72). In fact, VanderVeen
et al (2018) (69) demonstrated that ApcMin/+ mice, a genetic mouse model of colorectal cancer,
showed increased inflammation, which was accompanied by decreased muscle tissue weight,
muscle fatigability, and force production. In addition, C26 adenocarcinoma-induced cancer
cachectic mice revealed a decrease in specific force and myofiber cross-sectional area (CSA),
and a muscle fiber type shift towards a more glycolytic phenotype (70).
Furthermore, muscle force production is closely associated with the integrity of ECM in
that muscle force generated by the actomyosin cross-bridge mechanism transmits the force to
external tendons via the ECM (73). However, prior evidence showed disrupted ECM structure in
ApcMin/+ mice via accumulating non-contractile tissues such as connective tissue deposition (74).
Additionally, the matrix metalloproteinase (MMP) family of extracellular proteinases play an
important role in regulating the integrity of ECM via digesting essential ECM components such as
collagens, thereby interrupting the interaction between cells at the basement membrane and cellto-cell signaling, creating space for cancer cells to move forward and new blood vessels to form
to favor cancer cells, resulting in metastatic colonization (75). MMPs including MMP-2, -3, and -9
are identified to alter ECM architecture in skeletal muscle and a recent report reveals that these
MMPs were elevated as cancer develops, thereby increasing collagen deposition (76). However,
the regulation of ECM in CC has not been completely understood and additional investigations
are required.
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F. Protein Turnover in Cancer Cachexia

i.

Protein Degradation in CC
The major feature of CC is the net loss of skeletal muscle protein, which occurs when

protein degradation exceeds protein synthesis (77, 78). Prior evidence shows that pre-clinical
rodent models of CC exhibit elevated protein degradation while protein synthesis is suppressed
(79-82). Two major protein degradation processes, the ubiquitin proteasome system (UPS) and
the autophagy-lysosomal pathway (ALP) are often activated during muscle wasting conditions
including CC (78). These protein degradation systems are regulated via a transcription-dependent
pathway including activation of transcription factor FOXO, which are negatively controlled by
IRS/AKT pathway and NF-kB (78, 83, 84). In the UPS, ubiquitin is conjugated to target proteins
that are tagged and recognized through E3-E2 ubiquitin ligases, which are then degraded via the
ATP-dependent 26S proteasome(85). Two major atrophy-related genes, atrogin-1 (also known
as MAFbx) (86, 87) and MuRF1 (muscle RING finger protein 1) (86) and both atrogenes encode
E3 ubiquitin ligases, which initiate ubiquitination of target protein substrates (88-90), thereby
upregulating muscle atrophy. It should be noted that other atrophy-associated genes have been
recently described such as Growth arrest and DNA damage inducible alpha (GADD45a) and
Ubiquitin C (UBC) (91-93). These markers are elevated in various models of atrophy including
CC, disuse, and denervation-induced muscle wasting (81, 94, 95). Recent evidence from our
group also showed that elevated mRNA content of Atrogin-1 and MuRF1 and protein content of
ubiquitin were found in the skeletal muscle of Lewis Lung Carcinoma (LLC)-induced tumorbearing male mice 4 wks following tumor implantation (cachectic state) (81). A ~40% lowered
fractional synthesis rate (FSR) of mixed proteins was observed in muscle tissues in tumor-bearing
mice as well (81). Similar findings using the ApcMin/+ mouse (colon cancer model) have been
previously reported by the Carson group (36, 80), where significant reduction of muscle protein
synthesis and elevated E3 ligases are observed during the progression of CC. Interestingly, these
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lower E3 ligase activities were observed in both male and female animal models of muscle atrophy
including disuse (10) and CC (96), suggesting E3 ligases are a universal biomarker for many
different forms of muscle atrophy in both sexes.
Autophagy is a natural and conserved cellular homeostatic degradation and recycling
system that removes dysfunctional, unnecessary, long-lived proteins, or other organelles through
a lysosome-dependent mechanism (97). In the ALP, Beclin, LC3, and p62 play a critical role in
membrane formation, cargo transport, and selective removal of unnecessary organelles. During
the ALP, cytoplasmic components are targeted and isolated from the cell within a doublemembrane vesicle (autophagosome), which fuses with a lysosome, bringing its specialty process
of waste management and disposal; and eventually, becomes an autolysosome that are degraded
and recycled (98, 99) (Figure 1).

Figure 1. Autophagy-Lysosomal Pathways.
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ii.

Protein Synthesis in CC
Muscle protein synthesis is one of the two major components when it comes to net protein

balance while its role in CC has not been clearly understood. A reduced protein synthesis per se
can be responsible for the mechanism of atrophy (78). While our data (81, 82) and other works
(79, 80) clearly demonstrate reduced protein anabolism in pre-clinical animal models of CC,
understanding of the suppression of anabolic signaling remains incomplete (79, 100). The primary
cellular signaling pathway of muscle growth known as Akt/mTOR signaling is an essential part of
muscle protein synthesis (101, 102). It has been known that insulin and insulin-like growth factor
(IGF-1) initiate the protein synthesis (muscle hypertrophy) pathway by inducing phosphorylation
of Phosphoinositide 3-kinase (PI3K) and Protein kinase B (AKT), which leads to activation of
mammalian target of rapamycin (mTOR), whose downstream targets include, Ribosomal protein
S6 kinase beta-1 (p70S6K) and Eukaryotic translation initiation factor 4E (elF4E)-binding protein
1 (4E-BP1) (101). Previous evidence demonstrated that both 4E-BP1 and p70S6K were
downregulated in tumor-bearing mice (80), leading to lower muscle protein synthesis in the
cachectic state (80, 81). Downstream signaling of the mTOR promotes mRNA translation
initiation, thereby leading to generation of newly synthesized protein and increasing muscle mass
(103), and mTOR activation can be directly suppressed via its own inhibitors, DEP domaincontaining mTOR-interacting protein (DEPTOR) (104) and regulated in development and DNA
damage response 1 (REDD1) (105). Recent evidence demonstrated the expression of REDD1
has been upregulated in different forms of CC (6). in addition, our recent work also found elevated
DEPTOR protein content concomitant with reduced FSR of muscle protein in LLC-induced
cachectic male mice (81), indicating mTOR inhibition via DEPTOR/REDD1 as an essential hub
for regulation of muscle protein anabolism in CC. Ribosome biogenesis has emerged as one of
the main mechanisms regulating muscle hypertrophy (106), which is also implicated in different
forms of muscle atrophy (107, 108) although the precise role of ribosome biogenesis in CC has
not been explored.
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iii.

MAPKs in CC
Mitogen-activated protein kinase (MAPKs) are involved in many different cellular

regulations including cell proliferation, differentiation, mitosis, and apoptosis (109). To activate
MAPKs, it requires multiple phosphorylation events in their activation loops including ERK, JNK,
and p38 kinases (110). MAPKs are key regulators of both anabolic and catabolic signaling within
skeletal muscle (111, 112) and prior studies have suggested MAPKs are potent regulators of
cancer-induced muscle wasting (81, 113, 114). Sin et al (114) reported cancer-induced p38β
MAPK stimulated C/EBPβ acetylation, which is a key regulator to induce muscle wasting. Others
(113) also noted p38 MAPK links oxidative stress to autophagy-related gene expression in
cancer-induced muscle wasting. In addition, Li et al (115) revealed TNF-α acts via p38 to increase
atrogin-1/MAFbx mRNA level in skeletal muscle. This prior evidence is in line with our recent CC
study, where cachectic tumor-bearing male mice exhibited greater protein contents of ERK and
p38 MAPKs (81), suggesting MAPKs appear to be a central mediator of cancer-induced muscle
wasting although underlying mechanisms regarding cancer-induced muscle wasting are required
to be further elucidated.

iv.

Skeletal Muscle Regeneration in CC
An alternative factor that may contribute to muscle wasting in CC is altered skeletal muscle

regeneration (116). A detailed review on muscle regeneration during cancer cachexia has been
published elsewhere (117). Skeletal muscle has an efficient homeostatic capacity to regenerate
itself in response to injury and it can be hypothesized that skeletal muscle undergoes a
regeneration process in response to muscle wasting during CC. Accordingly, it is plausible that
cancer-induced muscle wasting is in part due to impaired muscle regeneration capacity
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dependently or independently of cellular signaling of protein synthesis. Interestingly, our group
has observed downregulated myogenic and cell cycle-associated markers including Cyclin D1,
Pax7, MyoD, and Myogenin at the early stages of cancer in tumor-bearing mice prior to cachectic
phenotypes and remained suppressed until marked weight loss occurs (81), indicating cancerinduced muscle atrophy might be partially contributed via impairment of the muscle regeneration
processes during early-stage cancer. Other work has shown that skeletal muscle regeneration is
impaired in tumor-bearing mice (118). Collectively, prior studies demonstrated pronounced
protein degradation, synthesis, MAPKs, muscle regeneration, and other factors associated with
muscle degeneration during CC although its individual contribution has not been well understood.

G. Role of Mitochondria in Cancer Cachexia

i.

Mitochondrial alterations during the development and progression of CC
Mitochondrial health and function have long been implicated with various human diseases

including CC (12-14). Prior studies have reported that mitochondrial quality control (MQC),
consisting of mitochondrial biogenesis, dynamics (fusion and fission) and autophagy (mitophagy)
(119, 120), is the basis for maintaining the integrity and stability of mitochondrial structure and
function, and is an important defense mechanism for cells to survive mitochondrial damage (121).
Mitochondrial dynamics consists of two distinct mechanisms; mitochondrial fusion and fission, the
balance between these two will determine mitochondrial network health (122). Mitochondrial
fusion occurs when two or more mitochondria fuse/join together, forming constantly changing
tubular organelles, and leading to mitochondrial elongation (122). Mitochondrial fusion mediators
differ between the inner and outer membranes of the mitochondria. Indeed, mitofusin (MFN1/2)
protein mediate fusion of outer mitochondrial membrane (OMM), while proteins including Optic
atrophy 1 (OPA1) mediates fusion between inner mitochondrial membrane (IMM) (122). On the
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contrary, mitochondrial fission proteins including Dynamic-1-like protein (DRP1) and
mitochondrial fission 1 protein (FIS1) control the final part of mitochondrial fission, pinching off
the membrane between two forming daughter mitochondria. Several DRP1-binding proteins
including mitochondrial fission factor (MFF)(123), binding DRP1 to induces mitochondrial fission
and FIS1, recruiting DRP1 to sites of fission (124). Damaged (fragmented) mitochondria are
separated by mitochondrial fission system and eliminated via autophagic lysosomal
sequestration, a process known as mitophagy (125). An appropriate balance between
mitochondrial fusion and fission allows for mitochondrial reorganization during biogenesis, which
is induced via various physiological responses including cellular stress or environmental stimuli
such as aerobic exercise (126-128). These physiological responses activate peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a) and its downstream including
TFAM and NRF2, thereby regulating mitochondrial biogenesis (126, 129-131) (Figure 2).

Figure 2. Mitochondrial quality control system.
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Dysregulation of muscle MQC from cancer-induced cachectic mice has been shown on
multiple occasions (12, 44); however, mitochondrial changes that occur during the development
of CC are underexplored. Previous studies have reported that both in vivo and in vitro models of
CC lead to impaired mitochondrial function including reduced respiratory capacity, ATP
production, and elevated reactive oxygen species (ROS) emission (18, 82, 132, 133).
Furthermore, elevated ROS emission has been implicated with impaired MQC (119, 120). Our
recent findings reveal elevated mitochondrial ROS emission and mitochondrial oxidative stress
precedes the development of CC in tumor-bearing male mice (12). In this study, elevated ROS
occurs concomitantly with reduced content of mitochondrial fusion regulatory proteins (OPA1)
during the pre-cachectic stage in tumor-bearing animals. In addition, markers for mitophagy
(BNIP3) and FIS1 were upregulated, and mitochondrial respiratory control ratio was impaired
during the cachectic phase (12). Similar results were reported by others that reduced
mitochondrial fusion, biogenesis, elevated mitochondrial fission, ROS emission, and protein
markers associated with autophagosome formation in both cachectic mice (18) and cancer
patients (134). Chronic elevation of mitochondrial ROS generation can increase rates of protein
degradation via activation of the ubiquitin proteasome-mediated protein breakdown process,
leading to muscle wasting (135). Although mitochondrial dysfunction is well studied in male tumorbearing mice (12, 18), it is still unclear/understudied whether the mitochondrial dysfunction would
occur in female counterparts. However, basal mitochondrial function and content are higher in
females (136) and female animals showed protective effects on mitochondrial health in different
forms of muscle atrophies such as disuse-induced (11). Based on the aforementioned
information, it is speculated that female tumor-bearing mice may protect against cancer-induced
muscle mitochondrial dysfunction compared to their male counterparts, thereby undergoing less
severe cachectic phenotypes. Taken together, our group showed alterations in mitochondrial
health and function during the early development of CC in tumor-bearing male mice and currently,
it is unknown if early targeting of H2O2 and mitochondrial fusion may prevent mitochondrial
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degeneration observed during CC in both sexes. Hence, additional supportive investigations on
targeting hydrogen peroxide (H2O2) and mitochondrial fusion are needed to elucidate
mitochondrial regulations during the development of CC.

ii. Mitochondrial Fusion Protein “OPA1” as a Potential Therapeutic Target for CancerInduced Muscle Wasting
OPA1 is a mitochondrially targeted GTPase that regulates mitochondrial fusion and cristae
structure in the inner mitochondrial membrane as well as contributes to ATP synthesis and
apoptosis (137-139). OPA1 localizes to the inner mitochondrial membrane, where it mediates
mitochondrial fusion in cooperation with MFN1/2 and other proteins to remodel cristae structure
(138, 140). Stabilization of mitochondrial by OPA1 protects against mitochondrial dysfunction,
ROS production, and other mitochondrial degenerations (141). Mutations of this gene have been
associated with severe mitochondrial dysfunction, apoptosis, dominant optic atrophy (leading to
a loss in vision), impairment in muscle contraction, and related dysfunctions (137, 142-144), many
of which are hallmarks of cancer (145, 146). Emerging evidence indicates OPA1 might be a key
molecular target for cancer biology and resistance to therapy. In fact, OPA1 was identified as one
of a few novel prognosis-associated genes in several cancers (147, 148). In addition, prior
evidence revealed mitochondrial dysfunction associated OPA1 cleavage contributes to muscle
degenerations such as reductions in myosin heavy chain protein (149) and Pax7 (a muscle stem
cell marker) (150), both of which are essential components regarding muscle growth. Prior
evidence demonstrated OPA1 participates in heat stress-induced cellular protection against
apoptotic stimuli and enhances the expression of heat shock protein (HSP) (151). In addition,
prior studies utilizing BGP-15 (HSP72 chaperone co-inducer, has recently been reported to
promote OPA1 protein content (152)) revealed that daily oral treatment of BGP-15 in rodents
resulted in increased mitochondrial number, oxidative capacity, and decreased insulin resistance
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Figure 3. OPA1-HSP70-BGP-15 axis as a potential target to attenuate cancer-induced muscle
degeneration
(153).

However, whether mitochondrial fusion regulatory proteins play an imperative role in

cancer-induced muscle wasting remains elusive (Figure 3).

Recently, our laboratory investigated molecular alterations during the development of CC
utilizing tumor-bearing male mice in a time-course experimental design (1 through 4 wks). In this
study, we found ~50% down-regulated OPA1
protein during the early development of CC (1
wk), which remained lower until cachectic
phenotypes occur (between 3- and 4-wk) (12).
Furthermore, my preliminary data showed a
reduction in myotube diameter via LCM (Lewis
lung

carcinoma-conditioned

media)

was

attenuated with LCM + BGP-15 intervention
(Figure 4), suggesting BGP-15 might be an Figure 4. Opa1 target (BGP-15) precents CC
in vitro. BGP-15 -known to induce Opa1.
important therapeutic target for cancer-induced BGP-15 prevent an ~10% loss in myotube
diameter by LLC conditioned media (LCM) in
muscle wasting. These findings led me to C2C12 myotubes. Different letters indicate
statistical significance (p<0.05).
pursue either phamacological (utilizing BGP-15
treatment in rodents) or genetic overexpression
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of OPA1 (OPA1 transgenic animal model) to determine whether it plays a pivotal role in cancerinduced muscle wasting in rodents. (Figure 5).

Therefore, the purpose of my dissertation is to investigate skeletal muscle alterations
during the development of CC in female tumor-bearing mice and determine the efficacy of OPA1
as a therapeutic target for cancer-induced muscle atrophy (Figure 5). Therefore, the CENTRAL
HYPOTHESES of this work are: Aim 1) Impaired muscle contractility, mitochondrial health, and
altered protein turnover will present in the skeletal muscle of female tumor-bearing mice and Aim
2) Impaired muscular health in response to LLC implantation will be ameliorated via AAVmediated OPA1 (mitochondrial fusion-associated) gene transfer.

Figure 5. Experimental design for OPA1-dependent pharmacological and genetic designs to
target cancer-induced muscle degeneration.

H. CONCLUSION
Progressive muscle loss is a hallmark for devastating conditions among cancer patients,
which reduces mobility and increases mortality. Most cancer patients are diagnosed with cancer
when cachectic phenotypes occur such as marked weight loss. Therefore, early diagnosis with
appropriate treatment is critical to improving cancer outcomes. Although understanding
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mechanisms of the early development of CC is crucial, most CC studies have mainly focused on
later or advanced stages of cancer. Another gap in CC research is regarding biological sex.
Although distinct phenotypical differences in skeletal muscle under normal or various myopathies
have been observed between sexes, most preclinical CC studies have been mainly focused on
males. These gaps in CC research make it difficult to suggest or provide effective therapeutic
strategies, hence future studies are warranted to investigate the development of CC and
suggested considering biological sex as an important variable. Therefore, the purpose of this
dissertation is to investigate skeletal muscle alterations during the development of CC in female
tumor-bearing mice and determine the efficacy of OPA1 as a therapeutic target for cancerinduced muscle atrophy. Many potential biomarkers have been suggested while mechanistic
efficacy using these biomarkers has not been successful. Recently, we found downregulated
OPA1 in the early development of CC. We hypothesize that targeting OPA1 with a timing of onset
of concurrent alterations to endogenous targets during the early development of CC will reveal
the importance of specific timing-derived treatment to prevent CC.
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CHAPTER II: PROPOSAL
A. Specific Aims
SEX DIFFERENCES IN CANCER CACHEXIA AND A NOVEL THERAPEUTIC TARGET FOR
CANCER-INDUCED MUSCLE WASTING
Cancer-cachexia (CC), a wasting syndrome, occurs in approximately 80% of cancer
patients (2) and is responsible for 22-30% of cancer-related deaths (2, 3). However, current
therapeutic approaches lack sufficient efficacy to prevent cachexia (3). Early biomarkers to
manage tumor development and concurrent treatment using potential therapeutic targets to
protect muscle mass are desperately needed to improve cancer outcomes. Recently, we identified
for the first time that mitochondrial degeneration including lower mitochondrial fusion protein,
OPA1, preceded marked loss in skeletal muscle mass of tumor-bearing mice, suggesting
OPA1 might be a novel target for cancer-induced muscle loss. However, the efficacy of OPA1
to prevent CC has not been assessed (12, 81).
In addition, the majority of preexisting pre-clinical CC studies have been mainly focused
on male animals (26, 45) although recent evidence demonstrates sex-related phenotypical
differences in response to muscle atrophy (45, 58, 154, 155). Therefore, the PURPOSE of my
dissertation project is to investigate skeletal muscle alterations during the development of CC in
female tumor-bearing mice (Aim 1) and determine the efficacy of OPA1 as a therapeutic target
for cancer-induced muscle atrophy (Aim 2). The CENTRAL HYPOTHESES of this proposed
work are: Aim 1) Impaired muscle contractility, mitochondrial health, and altered protein turnover
will present in the skeletal muscle of female tumor-bearing mice and Aim 2) Impaired muscular
health in response to LLC implantation will be ameliorated via AAV-mediated OPA1
(mitochondrial fusion-associated) gene transfer.
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AIM 1.
Define alterations in the development of cancer cachexia in female tumor-bearing mice.
Our laboratory has previously completed animal experiments for Aim 1. Female mice were
injected with Lewis Lung Carcinoma (LLC) and harvested at 1, 2, 3, and 4 wks to determine
skeletal muscle alterations during the development of CC. We utilized a similar experimental
design that we used with male mice (12), where we found mitochondrial degenerations in a precachectic state. Therefore, to define alterations of mitochondrial health in female mice, we
measured mitochondrial respiratory control ratio (RCR) and reactive oxygen species (ROS)
emission, oxidative phenotype, mitochondrial quality control markers. In addition, the cancerinduced muscle wasting mechanism has been well characterized in male animals and is
associated with a poor cancer outcome and reduced survival rate 13 although that of females
remains elusive. To determine the muscle wasting process from pre- to cachectic state, we further
assessed 24h protein fractional synthetic rate (FSR), protein degradation signaling via ubiquitin
proteasomal system (UPS) and autophagic-lysosomal pathway (ALP), pro-inflammatory markers,
and myogenic markers via immunoblotting and RT-qPCR. As muscle mass is directly associated
with strength, we finally assessed skeletal muscle contractility (force production and fatigability)
via in vivo electrical stimulation in lower limb muscles. The outcome of this project may provide
novel insight into potential mechanisms that may explain biological sex as a crucial variable
in cancer cachexia.
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AIM 2.
Define if genetic overexpression of OPA1 (OPA1/AAV) serves as a novel therapeutic
target for cancer-induced muscle wasting.
The research idea for aim 2 was developed from our prior studies of CC development to
define a mechanistic target of onset in CC. I will systemically determine the efficacy of promoting
mitochondrial quality by OPA1 gene manipulation in LLC-induced tumor-bearing mice to mitigate
cancer-induced muscle wasting. I will apply adeno-associated virus (AAV)-mediated gene
transfer of OPA1 gene into the muscle to prevent CC. Intra-muscular AAV has been applied in
muscle-related disease (156). Previously, we observed reduced OPA1 protein content during the
early development of CC which remained lower through development of the cachectic phenotype.
Therefore, the initial treatment and duration of the AAV intervention will begin at 1 wk following
LLC injection, and the gene transfer will continue throughout the animal experiment. To determine
if OPA1 AAV gene transfer attenuates CC, I will assess a diverse analysis to examine skeletal
muscle health. Specific skeletal muscle measurements will be followed as Aim 1. Briefly, muscle
contractile functions, fiber typing, protein turnover, mitochondrial oxidative phenotype, and
mitochondrial quality control will be assessed. The outcome of Aim 2 will provide mechanistic
evidence utilizing pre-CC signature for efficacious target in CC prevention.
*Note – our contingency plan for AAV was to utilize OPA1 transgenic mice to the
same purpose. As we did not have AAV prepared for this experiment in Aim 2 I present
data collected to date utilizing the OPA1 transgenic mice.
PUBLIC HEALTH IMPACT: Proposed project may significantly advance the current CC study via
providing a fundamental understanding of CC development in both males and females and a
mechanistic target to effectively prevent CC, contributing to improved overall cancer outcomes.
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C. RESEARCH STRATEGY

i.

SIGNIFICANCE
Cancer-cachexia (CC), a wasting syndrome, characterized by marked weight loss that

occurs in approximately 80% of cancer patients (2) and is responsible for 20-30% of cancerrelated deaths (2, 20). However, current therapeutic approaches lack sufficient efficacy to prevent
or reverse (3) and it is often poorly diagnosed (3). Understanding underlying mechanisms for the
development of CC are crucial for the development of therapies to treat CC and improve cancer
outcomes. Therefore, there remains a critical need to identify key underlying mechanisms
in the development of cancer cachexia in females to enhance therapeutic potential. The
OVERARCHING GOAL of this proposal is to understand alterations in skeletal muscle during the
development of CC in female tumor-bearing mice and determine if genetic intervention to promote
mitochondrial fusion protects muscle from wasting and attenuates CC. Therefore, the CENTRAL
HYPOTHESES of this proposed work are: Aim 1) Impaired muscle contractility, mitochondrial
health, and altered protein turnover will present in the skeletal muscle of female tumor-bearing
mice and Aim 2) Impaired muscular health in response to LLC implantation will be ameliorated
via AAV-mediated OPA1 (mitochondrial fusion-associated) gene transfer. Therefore, this
proposal will SIGNIFICANTLY address these critical needs and advance the study of cancer
cachexia via:
1. Providing FUNDAMENTAL evidence for alterations or degenerating processes in the
development of CC in female tumor-bearing mice as well as potential therapeutic strategies
to prevent CC via utilizing genetic manipulations (overexpression) of OPA1 based on our
previous findings (12). Furthermore, I will combine recent outcome measures incorporating
more complete assessments of mitochondrial health including mitochondrial function,
oxidative phenotype, quality control markers, and protein turnover including protein synthesis
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by 24h protein FSR as well as muscle contractile function to provide the most comprehensive
assessment of muscular health in CC development.
2. Providing MECHANISTIC evidence for targeting pre-muscle wasting alterations utilizing
genetic approaches. The AAV/OPA1 intervention will be employed with timing of onset based
upon the timing of concurrent alterations to endogenous target during the early development
of CC, which will provide the importance of specific timing-derived treatments and systemic
effects of the intervention to prevent CC.

ii.

RIGOR OF PRIOR RESEARCH
Our prior evidence using a pre-clinical mouse model of CC in a time-course manner

showed progressive deteriorations(12, 81), representing for the first time to define the precachectic signatures of
skeletal muscle in the
development of CC in
male tumor-bearing mice
(Table

1).

These

preliminary data indicate
that CC is responsible for
muscle

atrophy

and

mitochondrial dysfunction
in

male

tumor-bearing

mice, and it is speculated that certain biological markers may initiate these degenerating
processes during the initial stages of CC. Therefore, it is imperative to understand underlying
molecular mechanisms in both males and females during the development and progression of
CC to guide sex-based therapeutic strategies to prevent CC. This proposed project extends our
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prior studies in male mice (12, 81), and the outcomes of this proposal will help to advance
efficacious therapies for CC. Taken together, our preliminary studies show CC induces muscle
atrophy and mitochondrial dysfunction in the muscle of male tumor-bearing mice and supporting
the experimental rationale for the central hypothesis of this project.

D. APPROACH
Overall Approach. In Aim 1, I will provide novel evidence of pre-cachectic alterations in
the skeletal muscle during the early stages of CC via utilizing a time-course cancer development
design in female tumor-bearing mice. This time-course approach will allow us to identify and
compare degenerating mechanisms involved in muscle contractility, protein turnover, and
mitochondrial quality in the skeletal muscle during the development of CC, thus providing
foundational evidence in cachectic phenotypes in females. In Aim 2, I will provide mechanistic
evidence for targeting cancer-induced muscle wasting via utilizing a genetic intervention to
determine if rescuing OPA1 expression prevents CC-induced muscle wasting and cachectic
phenotypes. This approach will provide critical mechanistic insight into the development of CC in
females as well as a potential therapeutic target for cancer-induced muscle wasting in both sexes.
This combined strategy will allow us to shift from identifying pre-cachectic phenotypes in females
(Aim 1) towards advancing a mechanistic strategy to target CC (Aim 2).

i.

BIOLOGICAL SEX AS AN IMPORTANT VARIABLE.
Although it has been reported that muscle phenotype of both males and females respond

distinctively during different forms of muscle atrophy including disuse- (10) and inflammationinduced muscle atrophy (45), existing pre-clinical CC studies have been conducted predominantly
with male animals and it has not been tested if biological sex differentially regulates
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muscular health in the development of CC. Therefore, our animal experiments were performed
in female mice for Aim 1 to compare with previous male CC studies (12, 15, 35, 80, 81) and will
be performed in both sexes for Aim 2 to determine if there are distinct molecular alterations in the
skeletal muscle in response to genetic intervention between tumor-bearing males and females
within a study. Our unique research design may elucidate ambiguous roles in biological sex in CC
research.

ii.

RIGOR AND REPRODUCIBILITY.
Researchers involved in analyzing data will be blinded to experimental conditions although

binding to the tumor-bearing state during animal experiments are not feasible due to
subcutaneous allograft. Coding and analyzing data for immunoblotting, real-time PCR,
mitochondrial function and FSR will be blinded to laboratory members. Since our pre-clinical
animal model of CC is limited for translating into that of the human model, we have opted for a
relatively robust effect size (β>0.8) for power calculation. This robust effect size in highly
controlled pre-clinical models is more likely to translate into clinically meaningful results in human
models.
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E. AIM 1:
DEFINE ALTERATIONS IN THE DEVELOPMENT OF CANCER CACHEXIA IN FEMALE
TUMOR-BEARING MICE.

i.

EXPERIMENTAL RATIONALE.
With Aim 1, I will provide foundational insights into the development of CC and molecular

mechanisms involved during the early stages of CC. Prior investigations examining CC
progression have extensively focused on cachectic or refractory cachectic (late) states and
alterations during pre-cachectic (pre-weight loss) states remain elusive (80, 157), suggesting a
critical need in the study of CC. However, recent investigations from our group revealed that
disruptions of mitochondrial network (12) and satellite cell and myogenesis-associated genes (81)
precedes the development of cachectic phenotype in skeletal muscle in a mouse model of CC
and these markers are closely associated with mitochondrial respiratory function and muscle loss
that are often seen in cachectic states. Nevertheless, it remains unknown if these degenerating
processes are present in females during the development of CC. Prior observations demonstrated
that skeletal muscle undergoes marked atrophy and mitochondrial dysfunction in both tumorbearing male (12, 15) and female (82, 158) animals. However, females are known to be less
sensitive to inflammation-induced muscle atrophy compared to their male counterparts (45).
Therefore, I hypothesize altered muscle contractility, protein turnover, and impaired
mitochondrial quality/function in the skeletal muscle will be present during CC in female tumorbearing mice, but to a lesser extent compared to previous male CC studies (12, 81). However,
the pre-cachectic signature of female mice is not yet elucidated. Accordingly, determining and
comparing degenerative mechanisms between male and female skeletal muscle during the
development of CC will be critical to improve therapeutic strategies for the cancer treatment. Since
decreased muscle quality limits overall survival for cancer patients (159), identifying degenerative
mechanisms in the female during early stages of CC and specifically targeting these mechanisms
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will be a key step to reverse/prevent the cachectic state and improve cancer outcomes. Therefore,
we will determine if molecular degenerations occur in females during the development of CC.

ii.

EXPERIMENTAL DESIGN AND APPROACH.
Animal model and experimental design. Animal experiments and tissue analysis for

Aim 1 were already completed, therefore, Aim 1 will be described in the past tense. With Aim 1, I
utilized the LLC-induced mouse model of CC in a time-course manner to determine muscle
degenerating mechanism during the development of CC. LLC is a well-accepted allograft animal
model of CC and it has been widely used in various pre-clinical cancer researches (12, 81, 160)
due to enhanced experimental control including precise dosing making them an excellent
research model. Our novel time-course experimental design divides mice into 5 groups (1, 2, 3,
4 wks, and PBS control) and 1-4 wks mice were given LLC cells (1 x 10 6) suspended in PBS were
implanted to the hind flank at 8 wks of age. The tumors were allowed to develop for 1, 2, 3, and
4 wks and PBS-injected control mice were age-matched to the 4 wks of LLC-implanted mice and
tissues

were

harvested

at

4

different designated
time

points

as

described in Figure 1
(12). However, after
3 or 4 wks of tumor
growth, we observed
a clear dichotomy in
tumor size among 3 and 4 wks animals. Therefore, 3 and 4 wks mice were regrouped by Low
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Tumor (LT; ≤1.2g) and High Tumor (HT; ≥2g) weight after collecting the tissues, which allowed
us to determine and compare molecular changes occurred during CC between pre-cachectic and
cachectic states. A total of ~60 mice were utilized for Aim 1.

iii.

DEPENDENT VARIABLES.
To determine alterations in the skeletal muscle of female tumor-bearing mice in response

to LLC implantation, I set to assess dependent variables, which are as follows: 1) Muscle
contractility (peak isometric torque, ½ muscle relaxation time, time to maximal contraction, and
fatigability) of the dorsiflexor muscles of the lower limb was examined via utilizing in vivo electrical
stimulation as previously described (161, 162). This in vivo configuration system will allow me to
assess ankle torsion of the animal’s hind limb, as opposed to direct force. In addition, this
experiment is physiologically relevant and does not require surgical isolation nor neurovascular
alteration. The measurement of torque is normalized to estimates of cross-sectional area of the
plantaris muscle. Muscle contractility was measured 48 hours prior to the tissue harvest to ensure
any muscle damages occurred during the electrical stimulation are fully recovered prior to the
tissue harvest. 2) Protein turnover: Protein synthesis was assessed via 24h protein FSR via
Deuterium oxide (D2O) labeled amino acid (alanine) incorporation using gas chromatographymass spectrometry (GC-MS) as previously described (81). 24 hours of FSR of incorporated amino
acid will allow an assessment to occur over a full light/dark cycle and in the fed state, providing a
more direct reflection of protein synthesis in normal conditions. In addition, signaling for both
protein synthesis (via IGF/mTOR and its downstream pathways) and two major protein
degradation pathways via ubiquitin-proteasome system (UPS) and autophagic-lysosomal
pathway (ALP) were measured as previously reported by us using immunoblot and real-time
PCR(81). 3) Mitochondrial quality was assessed as we previously reported (12). Measures were
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mitochondrial RCR and ROS emission in permeabilized muscle fibers (12), mitochondrial network
using the fluorescent reporter gene; MitoTimer (12, 163), and mitochondrial quality control (MQC)
markers (mitochondrial biogenesis, dynamics, and mitophagy) via immunoblot and real-time
qPCR (12, 163). Mitochondrial RCR, ROS emission, and MitoTimer measurements were
performed at the time of tissue harvest and data analysis was already completed.

iv.

EXPECTED/OBSERVED OUTCOMES.
Based on what we (12, 81) and others (69, 80) observed from previous male CC studies,

we originally expected impaired muscle contractile function, mitochondrial quality, and abnormal
protein turnover in the skeletal muscle in tumor-bearing female mice compared to PBS-injected
control mice. We also expected a protective effect in tissue wasting and CC signatures in female
tumor-bearing mice in that females are less sensitive to inflammation-induced muscle atrophy
than males. Overall, female tumor-bearing mice developed cancer-induced muscle degenerations
including tissue weight loss, muscle contractility, abnormal protein turnover, and compromised
mitochondrial quality, but to a lesser extent compared to previous male tumor-bearing mice
reported previously (12, 81). More specifically, female tumor-bearing mice appear to have a
protective mechanism to prevent cancer-induced cachectic phenotypes including tumor
development, mitochondrial degeneration, and muscle wasting compared to previous male
studies.

v.

POTENTIAL PITFALLS AND CONTINGENCY PLAN.
Proposed animal experiments for Aim 1 were already completed, therefore we do not

anticipate any problems with study completion. However, the animal model I am utilizing in this

46
project is Lewis Lung Carcinoma-induced, which may not necessarily represent other cancer
types. This potential problem is likely to be solved via part of studies from our recently funded NIH
research grant/project (R01 AR075794-01A1/AR/NIAMS), which will test overall skeletal muscle
health assessments including skeletal muscle contractility, mitochondrial quality, and protein
turnover in different animal models of CC including C26 (colon cancer), and Azoxymethane (colon
cancer)-induced mouse models in both sexes, which will provide a more generalized view of CC
mechanisms in preclinical animal models.

vi.

STATISTICS AND SAMPLE SIZE DETERMINATION.
Data from each experiment will be assessed in two biological sexes independently. We

utilized a One-way analysis of variance (ANOVA) with independent factors of five different animal
groups. Where significant F-ratios were found, statistical differences among means were
determined by Tukey’s post hoc test. With an anticipated Cohen’s f effect size of 0.35, α=0.05,
and β=0.80 and I required 10-12 animals per condition.
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F. AIM 2.
DETERMINE IF MITOCHONDRIA-TARGETED INTERVENTION PREVENTS CC.

i.

EXPERIMENTAL RATIONALE.
Our laboratory has shown that mitochondrial

inner

membrane

fusion

protein

(OPA1)

is

downregulated during the early development of
cancer and remains suppressed until cachectic
phenotypes occur in male tumor-bearing mice
(Figure 2.) (12). Therefore, I will apply a novel
therapeutic strategy (a timing-dependent OPA1 gene
manipulation) to attenuate LLC-induced muscle
atrophy

via

the

mitochondria-targeted

genetic

methodology. Although whether the downregulation
of OPA1 observed in male tumor-bearing mice would
appear in females was unknown, prior evidence from our laboratory demonstrated lower OPA1
mRNA level in both male and female mice of disuse-induced muscle atrophy. This experiment
will allow a guided approach to preventative treatment in cancer-induced muscle wasting while
providing crucial mechanistic insight into the development of CC. Optic atrophy 1 (OPA1) is the
mitochondrial inner membrane remodeling protein and acts as a fusion factor via combining two
mitochondrial pieces (fusion). OPA1 has a dual role in maintaining morphology and energetics
via mediating inner membrane fusion and regulating cristae structure (164). OPA1 also plays a
crucial role in mitochondrial oxidative phosphorylation and calcium homeostasis (165). In addition,
prior evidence demonstrated conditional OPA1 deletion resulted in lower muscle mass as well as
elevation of catabolic signaling and suppression of protein synthesis (166). Meanwhile,
overexpression of OPA1 improved motor function, respiratory chain activity, and increased
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lifespan

in

a

pre-clinical

mouse

model

of

mitochondrial disease (167). Despite the therapeutic
potential of rescuing OPA1 on muscle mass, the
efficacy of OPA1 has not been assessed in certain
forms of muscle atrophy including cancer-induced
muscle atrophy. Previously, we observed impaired
mitochondrial quality control markers including OPA1
(Figure 2) during the early development of CC prior
to a marked muscle loss (12). Here I suggest
rescuing OPA1 may be critical to have protective
effects on mitochondrial degeneration and protein catabolism in CC. Smuder et al revealed that
HSP72 overexpression via BGP-15 (a nicotinic amidoxime derivative, which induces OPA1 and
HSP72 expression) administration had protective effects against mechanical ventilation-induced
oxidative stress and transcriptional activities of protein degradation (168).

Accordingly, we

assessed the efficacy of OPA1 via using BGP-15 in LLC-conditioned media (LCM)-mediated
myotube atrophy in vitro and we found myotube atrophy induced via LCM was rescued with BGP15 overexpression (Figure 3). These preliminary data led us to pursue in vivo animal studies
using a mouse model of OPA1 (AAV-mediated gene transfer) to determine the role of OPA1 in
tumor-mediated muscle atrophy in vivo. By using this experimental design, I hypothesize that
reduced muscle tissue weights via tumor implantation will be attenuated in mice treated with AAVmediated gene transfer. Moreover, prior evidence demonstrated that OPA1 plays an imperative
role in both mitochondrial oxidative phosphorylation and protein turnover (165, 166). Therefore,
our experimental intervention utilizing genetic overexpression of OPA1 in mice is likely to rescue
mitochondrial and muscular degenerations induced via tumor growth.
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*Note – our contingency plan for AAV was to utilize OPA1 transgenic mice to the
same purpose. As we did not have AAV prepared for this experiment in Aim 2 I present
data collected to date utilizing the OPA1 transgenic mice.

ii.

EXPERIMENTAL DESIGN AND APPROACH.
First, a mouse model of cancer cachexia will be applied using LLC implantation in

C57BL6/J male and female mice and allow to grow the tumor for 4 wks to become a cachectic
state. I will use AAV-mediated gene transfer to the tibialis anterior (TA) of tumor-bearing mice at
a designated time point (from 1 wk after the tumor-implantation). AAV will allow high efficiency
(90%) and stability of gene transfer, which has been successfully used for long-term gene
expression in vivo in various tissues including skeletal muscle (156, 169). AAV plasmid will be
driven by the U6 polII promoter and express a green fluorescent protein (GFP) to allow
identification of transfection positive fibers and efficiency. AAV/OPA1 (overexpression vector) will
be transferred via intramuscular injection into both TA muscles while control mice will be given

the appropriate control vector AAV. Further efficiency of AAV plasmid transfer will be provided
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with immunohistochemistry and RT-qPCR data. This will provide an excellent method of temporal
OPA1 gene transfer, allowing me to investigate skeletal muscle health including muscle
contractility, protein turnover, and mitochondrial quality in response to LLC-induced muscle
atrophy (Figure 4). The total number of animals for Aim 2 will be ~88 mice. Specifically, there will
be 4 animal groups (12 animals per group) within each sex for each approach (PBS-Control/AAV
vs PBS-OPA1/AAV vs LLC-Control/AAV vs LLC-OPA1/AAV). By utilizing these gene
manipulation method, I will not only provide fundamental information regarding the efficacy of
OPA1 genetic intervention in cancer-induced muscle atrophy but also proof of concept for the
efficacy of timed interventions to stage of tumor development.

iii.

DEPENDENT VARIABLES.
Dependent variables will be the same for both Approach 1 and 2. To determine overall

muscular health in response to genetic intervention (AAV OPA1 gene transfer and OPA1 TG), I
set to assess dependent variables including 1) Muscle contractility, 2) Protein turnover, and
3) Mitochondrial quality will be assessed as in Aim 1.

iv.

EXPECTED OUTCOMES.
1) 4 wks of LLC implantation will induce significant tissue wasting including skeletal muscle

and fat as we have seen previously (12, 81) 2) 4-wk of LLC implantation will also induce muscle
degenerating effects including impaired muscle contractility, abnormal protein turnover, and
degenerated mitochondrial health.

3) Genetic overexpression of OPA1 will attenuate LLC-

induced muscle degenerations including muscle atrophy, abnormal protein turnover, impaired
muscle contractility, and mitochondrial health. 4) Based on previous evidence (12, 45, 61, 81,
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170), I also expect to observe sex differences in 1), 2) and 3). Specifically, I expect relatively less
severe tissue wasting, muscle fatigability, and mitochondrial oxidative capacity in female mice
than previous male studies (12, 81).

v.

POTENTIAL PITFALLS AND CONTINGENCY PLAN.
Approach 1 in Aim 2 is required specific techniques including AAV subcloning, production,

and utilization. These procedures will be led by Dr. Christopher Nelson who is experienced in the
required skills; therefore, I do not anticipate any technical problems. However, in case of
difficulties in AAV mediated gene expression, I will concomitantly perform experiments with OPA1
TG mice. These mice were developed and validated by the laboratory of Dr. Luca Scorrano (167).
Skeletal muscle specific OPA1 TG mice will be given LLC-implantation and the tumors will
develop for 4 wks and the same assessments for Aim 2 will be applied to determine if OPA1 TG
mice exhibit any protection effects against cancer-induced muscle degenerations.
*Due to unavailability of OPA1 AAV plasmid, OPA1 TG animals were used to test
my central hypothesis for Aim 2. In addition to OPA1 TG animals, BGP-15 (pharmacological
target of OPA1) was utilized in both in vitro and in vivo to further test the efficacy of OPA1.

vi.

STATISTICS AND SAMPLE SIZE DETERMINATION.
Data from each experiment will be assessed in both biological sexes. Data will be

assessed by two-way analysis of variance (ANOVA) with independent factors of sex
(males/females) by tumor-bearing (tumor vs control) by plasmid (AAV/OPA1 vs AAV/empty vector
control). When significant F ratios are found, pairwise comparisons will be Tukey Post-hoc
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adjusted. With an anticipated Cohen’s f interaction effect size of 0.35, α=0.05, and β=0.80 we
anticipate requiring 12 animals/condition.

G. PROPOSED TIMELINE OF ENTIRE PROJECT.
All proposed experiments are planned based on logical relationships and expected time
to complete the entire project within 12 months as described in the timeline table. Aims are
designed independently of each other, and the proposed arrangement will allow me to facilitate
this project in a timely progress manner. There are no anticipated budget problems to complete
both aims as well (Table 2).
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CHAPTER III: Manuscript from Specific Aim I

Development of metabolic and contractile alterations in development of cancer cachexia
in female tumor-bearing mice.

Seongkyun Lim & Nicholas P. Greene
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A. Graphical Abstract
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B. ABSTRACT
Cancer cachexia (CC) results in impaired muscle function and quality of life and is the
primary cause of death for ~20-30% of cancer patients. We demonstrated mitochondrial
degeneration as a precursor to CC in male mice, however, if such alterations occur in females is
currently unknown. The purpose of this study was to elucidate muscle alterations in CC
development in female tumor-bearing mice. 60 female C57BL/6J mice were injected with PBS or
Lewis Lung Carcinoma at 8 wks age, and tumors developed for 1, 2, 3, or 4 wks to assess the
time course of cachectic development. In vivo muscle contractile function, protein fractional
synthetic rate (FSR), protein turnover, and mitochondrial health were assessed. 3- and 4-wk
tumor-bearing mice displayed a dichotomy in tumor growth and were reassigned to High Tumor
(HT) and Low Tumor (LT) groups. HT mice exhibited lower soleus, TA, and fat weights compared
to PBS. HT mice showed lower peak isometric torque and slower one-half relaxation time
compared to PBS. HT mice had lower FSR compared to PBS while E3 ubiquitin ligases were
greater in HT compared to other groups. Bnip3 (mitophagy) and pMitoTimer red puncta
(mitochondrial degeneration) were greater in HT while Pgc1α1 and TFAM (mitochondrial
biogenesis) were lower in HT compared to PBS. We demonstrate alterations in female tumorbearing mice where HT exhibited greater protein degradation, impaired muscle contractility, and
mitochondrial degeneration compared to other groups. Our data provide novel evidence for a
distinct cachectic development in tumor-bearing female mice compared to previous male studies.

KEYWORDS: Mitochondrial function, muscle atrophy, mitochondrial quality control, Lewis Lung
Carcinoma, and skeletal muscle contractility.
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NEW & NOTEWORTHY Our study demonstrates divergent tumor development and tissue
wasting within 3- and 4-wk mice, where approximately half the mice developed large tumors and
subsequent cachexia. Unlike previous male studies, where metabolic perturbations precede the
onset of cachexia, females appear to exhibit protections from the metabolic perturbations and
cachexia development. Our data provide novel evidence for divergent cachectic development in
tumor-bearing female mice compared to previous male CC studies, suggesting different
mechanisms of CC between sexes.
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C. INTRODUCTION
Cancer is the second leading cause of death worldwide and about 600,000 people die
from cancer each year in the United States (171). 50-80% of cancer patients experience the
wasting syndrome known as cancer cachexia (CC) which is inversely associated with healthrelated quality of life (3, 172). CC is a multifactorial wasting syndrome characterized by significant
skeletal muscle mass loss with or without loss of fat mass that may not be reversed by nutritional
intervention alone and is responsible for 20-30% of cancer-related deaths (3). Moreover, cachexia
is often clinically defined by greater than 5% unintentional weight loss over the past 6 months,
which often is associated with progressive dysfunctions or degenerations in multiple tissues and
organs (3). Unfortunately, there are limited treatments that mitigate the effects of CC. Therefore,
appropriate early diagnosis and treatment of cancer-induced cachexia continues to be the most
effective strategy to alleviate this condition. Furthermore, understanding the pre-cachectic
processes and the development of preventive approaches become crucial. However, while we
have provided recent evidence for such pre-cachectic processes in male tumor-bearing mice (12,
81, 173), to date there is limited understanding of pre-cachectic processes in females.
Previous evidence has suggested impaired skeletal muscle oxidative capacity may reduce
muscle mass in the cachectic state (15), although the initial mechanisms remain elusive.
Accordingly, we have focused on aspects of mitochondrial health including mitochondrial
respiratory control ratio (RCR) and reactive oxygen species (ROS) emission during the
development of CC in male mice revealing that mitochondrial degeneration precedes the
cachectic phenotypes in skeletal muscle of tumor-bearing male mice (12). Prior evidence denoted
that elevated oxidative stress has been linked to altered protein turnover and skeletal muscle
integrity (174). Oxidative stress to proteins yields increases in the hydrophobicity of both
intracellular and cytoplasmic proteins, which are often toxic and can threaten cell viability,
inducing protein aggregation, thereby undergoing selective proteolysis (175). Specifically, we
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found smaller cross-sectional area (CSA) of muscle fibers and lower protein fractional synthesis
rates (FSR), as well as altered cellular signaling associated with protein turnover in LLC (Lewis
Lung Carcinoma)-induced cachectic male mice (81), in line with the previous works (15, 176).
There is a growing body of evidence suggesting distinct biological sex differences in
different models of animal muscle atrophy (10), with phenotypical disparities between males and
females having been found in different forms of human cancers including lung cancer (177). In
fact, males appear more susceptible to inflammation-mediated muscle atrophies with greater
ubiquitin-proteasome system (UPS) (12, 45) while females seem more susceptible to disuseinduced muscle atrophies with lower UPS compared to males (45, 62). Moreover, recent evidence
from our laboratory suggests sex-based differences in the development of muscle disuse atrophy
(10). Notably in cancer cachexia male Apc Min/+ mice demonstrate a high IL-6 dependency for
cachexia development while female mice exhibit an IL-6 independence (9, 15, 64). While the initial
development of cancer cachexia in male mice is a relatively understudied topic, investigations of
the same pathology in female mice are very few despite suggestions of differing atrophic
mechanisms between biological sexes. Therefore, the purpose of this study was to assess the
pre-cachectic signature of skeletal muscle in the development of CC in female tumor-bearing
mice. Specifically, herein, we have focused assessment on aspects of muscle contractile function,
protein turnover, and mitochondrial health.
Footnote: All figures can be found at the end of chapter III.
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D. METHODS

i. Animal Interventions
All animal methods were approved by the Institutional Animal Care and Use Committee
of the University of Arkansas. 60 female C57BL/6J mice (n=10-14/cohort) were purchased from
Jackson Laboratories (000664, Bar Harbor, ME, USA) and kept on a 12:12-h light-dark cycle,
housed at 72 degrees Fahrenheit, and given ad libitum access to normal rodent chow and water
for the duration of the study. At 8 wks of age, mice were subcutaneously given an injection of
either Lewis Lung Carcinoma (LLC) cells (1 x 10 6) suspended in 100 μL sterile phosphate-buffered
saline (PBS) or an equal volume of sterile PBS as a control to the left hind flank. Per our prior
works (12, 173), tumors were allowed to develop for 1, 2, 3, or 4 wks. PBS control mice were agematched with 4 wks tumor-bearing mice at time of tissue collection. After 3 or 4 wks of tumor
growth, we noted a clear dichotomy in tumor size, with some females having greater tumor
development than others within 3 and 4 wks animals. Therefore, 3 and 4 wks mice were combined
and regrouped by Low Tumor (LT; ≤1.2g) and High Tumor (HT; ≥2g) bearing groups
(Supplemental Figure 1A-B). Tissue collection was performed at 12 wks of age for 4 wks as well
as PBS mice and the rest of the mice were euthanized at the designated time points and tissue
wet weight was measured. Plasma was separated from the blood by centrifugation to determine
female sex hormones. Tissue and plasma samples were then snap-frozen in liquid nitrogen and
stored at -80 °C for further analysis. All tissue weights were normalized to their tibia length to
account for different body sizes (81). Final groups for analysis included PBS, 1wk, 2wk, LT, and
HT.
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ii. Lewis Lung Carcinoma Cell Culture
LLC cells (CRL-1642, ATCC, Manassas, VA, USA) were plated in 250 mL culture flasks
in DMEM (11965092, Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum
(26140079, Life Technologies) supplemented with 1% penicillin/streptomycin (15140122, Life
Technologies) and media was changed every 48 hours. Upon ~80% confluence, cells were
trypsinized, suspended via centrifugation, and diluted in PBS prior to tumor implantation as
previously described (12).

iii. Plasmid DNA Amplification and Electroporation
DH5-α Escherichia coli containing pMitoTimer plasmid were amplified and plasmid DNA
isolated using PureLink HiPure Plasmid Filter Maxiprep kit (K211017, Life Technologies). At 6
wks of age, pMitoTimer plasmid transfection into the right flexor digitorum brevis (FDB) muscle
was performed as described previously (12, 163). Briefly, while mice were anesthetized
(isoflurane), 10 μL of 0.36 mg/mL of hyaluronidase in saline was injected using an insulin syringe
with a 30-gauge needle subcutaneously under footpad. The needle penetrates the skin at a point
close to the heel of the foot and advances the needle subcutaneously towards the base of the toe
for ¼ which is above the FDB muscle. After 60-min, mice were anesthetized again and a total of
20 μg of the plasmid DNA for MitoTimer was injected subcutaneously in the footpad with the same
procedure described for the hyaluronidase injection. Anesthesia was disconnected after the
plasmid DNA injection for 10-min and reconnected for electroporation. Two gold-plated
acupuncture needles were connected to an electrical stimulator placed under the skin near the
heel and a second one near the base of the toes. Electrodes were perpendicular to the long axis
of the foot and parallel to each other. 10 electrical pulses with 20 ms in duration/each, at 1 Hz and
75 V were applied using an S88 electrical stimulator (Grass Telefactor, West Warwick, RI, USA).
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iv. In vivo Muscle Contractility Test
Approximately 48 hours prior to tissue harvest, in vivo peak isometric torque, isometric
torque frequencies, frequency at half maximum torque, 1/2 relaxation time, time to maximal
contraction, and fatigability (susceptibility to fatigue) of the anterior crural (shin) muscles were
performed as described (161). Briefly, while mice were anesthetized, the left hindlimb was shaved
and an ethanol pad applied to clean the skin. The foot was placed in a footplate attached to a
servomotor (Model 300B-LR, Aurora Scientific, Aurora, Ontario, Canada) using surgical tape
while their body temperature was maintained at 37 °C using a heating pad. Two platinum
electrodes (Model E2–12, Grass Technologies) were then inserted percutaneously on either side
of the peroneal nerve. Consistent instant stimulation was monitored to ensure the electrodes were
neither too deep nor too proximal as to yield recruitment of the posterior crural muscles. Muscle
contractions were induced via electrical stimulator and stimulus isolation unit (Model S48 and
SIU5, respectively; Grass Technologies). After resting the hindlimb for 1-min, torque and M-wave
as a function of stimulation frequency were measured during 12 isometric contractions with the
duration of 150 ms at various stimulation frequencies (10, 20, 30, 40, 60, 80, 100, 125, 150, 200,
250, and 300 Hz) to determine hindlimb motor unit recruitment based on two different
physiological conditions: [1] hindlimb motor unit recruitments during normal movement, which
occurs between 60 and 100 Hz (178). [2] During supra-maximal stimulation frequencies (i.e., >200
Hz) can reveal different contractile phenotypes such as low-frequency fatigue (179) followed by
resting the hindlimb for 4-min. After measurement of submaximal and maximal isometric torques
at 150 Hz, the anterior crural muscles underwent a fatigability test via applying 120 isometric
contractions with duration of 150 ms per each stimulation at 40 Hz for a total protocol time of 2 min. During the recovery following the fatigability test, the normal movement of experimental mice
was closely monitored to determine any injuries during the in vivo muscle force production and
fatigability test.
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v. Deuterium (D2O) Injection & 24 hours Muscle Fractional Synthesis Rate (FSR)
FSR was quantified using gas chromatography-mass spectrometry (GC-MS) (7890A and
5977A, Agilent, Santa Clara, CA, USA) as described (10, 81). Briefly, mice were given an
intraperitoneal (IP) injection of 99.9% D2O (151882-1L, Millipore Sigma, Burlington, MA, USA) at
20 μL/g body weight 24 hours prior to tissue harvest. Drinking water was thereafter supplemented
with 4% D2O to maintain the plasma pool of D2O until tissue harvest (180). Mice were not fasted
at tissue collection. 15 mg of gastrocnemius and TA muscles were powdered and homogenized
in a 10% TCA solution for FSR. Mixed protein fractions were then washed three times with 10%
TCA solution by centrifugation to eliminate cytosolic amino acids. Proteins were then placed in a
tube with 200 μL of 6 M HCL and heated at 100 °C to hydrolyze proteins into amino acids for 24
hours. An aliquot of the hydrolysate was dried down and derivatized with a 3:2:1 v/v solution of
methyl-8, methanol, and acetonitrile to determine 2H labeling of alanine on its methyl-8 derivative.
The solution was then placed in a GC–MS capillary column (7890A GC HP-5 ms capillary column,
Agilent) and positioned in the GC–MS; 1 μL of the solution was run on the GC–MS at a 20:1 split.
GC–MS settings have previously been described (79). A ratio of deuterated alanine over alanine
was employed to assess protein synthesis. The precursor pool of 2 H 2O in the plasma was reacted
with 10 M NaOH and a 5% solution of acetone in acetonitrile for 24 hours to conjugate the free 2
H2O to acetone. The solution was extracted by adding Na 2SO4 and chloroform and placed in
capillary columns to be analyzed on the GC–MS to detect acetone at a 20:1 split. FSR of mixed
proteins were calculated using the equation EA × [EBW × 3.7 × t (h)] - 1 × 100, where EA
represents the amount of protein-bound [2H] alanine (mole% excess), EBW is the quantity of
2H2O in body water (mole % excess), 3.7 represents the exchange of 2H between body water
and alanine (3.7 of 4 carbon-bound hydrogens of alanine exchange with water) and t (h)
represents the time the label was present in hours.
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vi. Fluorescence Microscopy for pMitoTimer
pMitoTimer was analyzed as previously described (12). Briefly, at the time of tissue
harvesting, freshly collected FDB muscles were fixed with 4% paraformaldehyde (PFA) for 20min followed by 5-min incubation with PBS at room temperature. Muscles were then spread out
on a gelatin-coated glass slide using 2 forceps and mounted with a drop of 50% glycerol in PBS
as mounting media. A coverslip was added on the top of the mounted sample and 4 drops of nail
polish were applied at the corners to anchor the coverslip. pMitoTimer images were acquired at
x100 magnification using the FITC (green; excitation/emission, 488/518 nm) and TRITC (red;
excitation/emission, 543/572 nm) fluorescent channels on a Nikon Eclipse Ti-S inverted epifluorescent microscope (Nikon, Melville, NY, USA) with LED-based light source. Standardized
acquisition parameters were established and followed for all imaging to match across samples.
All assessments were performed in congruence with Laker et al (163). A specially generated
MATLAB program, a generous gift from Dr. Zhen Yan (U. Virginia), was used to analyze
pMitoTimer red to green ratio (a mitochondrial oxidative stress marker) and pure red puncta
number (a marker for completely degenerated mitochondria) (163).

vii. Cryosection & Succinate Dehydrogenase (SDH) Histological Staining
Cryosections and all histological staining methods were performed as described (12).
Plantaris muscle was embedded with optimal cutting temperature (OCT) and frozen in liquid
nitrogen-cooled isopentane. Each section was cut at 10 μm using a Leica CM1860 cryostat (Leica
Biosystems, Wetzlar, Germany). Sections were stained for SDH. Sections were in incubation
media (50 mM sodium succinate, 50 mM phosphate buffer, 0.12 M KH 2PO4, and 0.88 M Na2PHO4,
0.5 mg/mL nitroblue tetrazolium) for 40-min in a 37 °C water bath. Slides were washed for 3-min
with dH2O and imaged. Images were collected with Nikon Sight DS-Vi1 camera mounted on an
Olympus CKX41 inverted microscope. ~25 individual fibers of SDH+ (purple or oxidative) and
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SDH- fibers (non-purple or glycolytic) per each muscle were counted and both fibers were
manually circled for cross-sectional area (CSA) using Nikon Basic Research Imaging Software
(Melville, NY, USA). All fiber measurements were performed by a blinded investigator. Plantaris
muscle was initially chosen to compare current SDH data with our previous male CC study (12).

viii. Preparation of Separated and Permeabilized Muscle Fibers
During tissue harvesting, ~15 mg of fresh plantaris muscle was collected and placed in
100 mm rounded petri dish containing ice-cold buffer X (60 mM K-MES, 35 mM KCl, 7.23 mM
K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM taurine, 5.7 mM ATP, 15
mM phosphocreatine, and 6.56 mM MgCl2 at pH 7.1). Connective tissues and blood clots were
eliminated, and the fiber bundles were gently separated into a near-single fiber bundle to
maximize their surface area under an upright stereoscopic microscope (Fisher Scientific,
Waltham, MA, USA) using a pair of extra-sharp forceps (Fisher Scientific). The finely separated
fiber bundles were then permeabilized in a tube with saponin (50 μg/mL) in ice-cold buffer X on a
rotator for 30-min at 4 °C. The permeabilized fiber bundles were washed in ice-cold buffer Z (110
mM K-MES, 35 mM KCl, 1 mM EGTA, 5 mM K2HPO4, 3 mM MgCl2, 0.005 mM glutamate, 0.02
mM malate, and 0.5 mg/ml BSA at pH 7.1) for 5-min x 3 times as previously described (12, 181).
The permeabilized fiber bundles were then used for both mitochondrial RCR and ROS emission
(12).

ix. Mitochondrial Respiratory Control Ratio (RCR)
Mitochondrial oxygen consumption was measured by polarography in a respiration
chamber maintained at 37 °C (Oxygraph+, Hansatech Instruments, King’s Lynn, UK) as described
(12) and this method was adapted from Min et al (181). Briefly, permeabilized plantaris muscles
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were transferred to a respiratory chamber filled with 1 mL of respiration buffer Z containing
creatine (20 mM) to saturate creatine kinase and allowed to equilibrate with the tissue for 5- to
10-min before adding any substrate. State 2 respiration was assessed by the addition of malate
and pyruvate (5mM) using 10 μL 701RN Syringes (Hamilton, Reno, NV, USA) followed by
maximal ADP-stimulated respiration (State 3) by adding ADP (0.25 Mm) and then basal
mitochondrial respiration (State 4) by the addition of oligomycin (10 μg/mL) to inhibit ATP
synthesis. State 3 and 4 respiration rates were normalized to dry tissue weight. The respiratory
control ratio (RCR) was calculated by dividing State 3 by State 4 respiration.

x. ROS Emission
ROS emission was determined using Amplex UltraRed Reagent (Molecular Probes,
Eugene, OR, USA) in permeabilized muscle fibers as previously described (12). This assay is
based on the concept that amplex red reacts with H2O2 in a 1:1 stoichiometric ratio in the presence
of horseradish peroxidase to produce the red fluorescent oxidation product; resorufin. Following
the addition of the permeabilized plantaris muscle, baseline H 2O2 production was measured
followed by induction of H2O2 production by the addition of supraphysiological concentrations of
succinate. The rate of H2O2 was normalized to dry weight of the tissue and calculated based on
the rate of change from baseline to succinate and then concentrations we calculated using a
standard curve. Plantaris muscle was used for both mitochondrial respiration and ROS emission
analysis.

xi. Immunoblotting
Frozen gastrocnemius muscle samples were powdered, and 20 mg tissue samples were
suspended in 250 μL 2x protein sample buffer (50 mM Tris-HCl, 1% sodium dodecyl sulfate
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(SDS), 10% glycerol, dithiothreitol (20 Mm), 2-mercaptoethanol (127 mM), and 0.01%
bromophenol blue combined with protease inhibitors, and phosphatase inhibitors at pH 6.8) and
homogenized. Protein concentration was determined using the RC/DC assay (5000122, Bio-Rad,
Hercules, CA, USA). 40 μg total protein in protein sample buffer was loaded into 10% gel and
resolved by SDS-PAGE at 100 V for 2 hours, transferred to a PVDF membrane at 20 V for 1.5
hours. Ponceau S stain was applied to membranes. The membranes were then incubated with
5% of milk in TBS at room temperature for 1 hour, then the membranes were incubated with
primary antibodies with 1:500-1000 dilution rate in LI-COR blocking buffer with 0.2% tween 20.
The membranes were incubated overnight for primary antibodies specific to COX-IV (4844S, Cell
Signaling,), VDAC (4866S , Cell Signaling), Deptor (ABS222, Millipore Sigma), Ubiquitin (3933,
Cell signaling), Beclin-1 (3737, Cell Signaling), LC3 (4108, Cell signaling), p62 (p0067, Sigma),
p-p38 MAPK (9211, Cell signaling; T180/182), p38 MAPK (9212, Cell signaling), p-ERK 1/2 MAPK
(4370, Cell signaling; T202/Y204 ), ERK 1/2 MAPK (4695, Cell signaling), PGC-1α (sc-13067,
Santa Cruz), PPARα (sc-9000, Santa Cruz), PPARδ (sc-7197, Santa Cruz), TFAM (7495, Cell
Signaling), MFN1 (sc-50330, Santa Cruz), MFN2 (sc-50331, Santa Cruz), OPA1 (sc-367890,
Santa Cruz), DRP1 (14647, Cell Signaling), and FIS1 (NB100-56646, Novus). BNIP3 (3769, Cell
Signaling), SOD1 (GTX100554, Genetex), SOD2 (131945, Cell Signaling), SOD3 (AF4817, R &
D Systems), and Catalase (140975, Cell Signaling). Following overnight incubation with primary
antibodies, membranes were washed with TBS with 0.1% tween 20 (TBST) for 5-min x 3 times
and conjugated with HRP secondary antibodies (LI-COR Biosciences, Lincoln, NE, USA) with
1:10,000 dilution rate were used according to the manufacturer’s protocol for an hour at room
temperature. Membranes were then washed with TBST for 5-min x 3 times followed by an image
scan on LiCor Odyssey FC via IR detection. All bands were normalized to the 45 kDa actin band
of Ponceau S stain as a loading control as previously described (12, 182, 183).
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xii. RNA isolation, cDNA synthesis, and quantitative real-time PCR
Frozen gastrocnemius muscle samples were powdered, and 20 mg tissue samples were
suspended in 1 mL of TRIzol reagent and homogenized using Polytron for ~5-sec x 5 times before
being transferred into a 1.5 mL microtube placed on ice. After 15-min at room temperature, 200
μL of chloroform was added and samples were centrifuged for 25-min. The clear portion of the
solution from the top was transferred into a new tube. An equal amount of 70% of Diethyl
Pyrocarbonate (DEPC) treated ethanol was added, and the samples were loaded into a RNeasy
column. RNA isolation was then processed using an RNA isolation kit (K145002; Invitrogen,
Carlsbad, CA, USA). 30 μL of DNase treated RNA was collected and RNA concentration and
purity were determined by fluorometry using 260/280 nm ratios read on a Bio-Tek Power Wave
XC microplate reader (BioTek Instruments Inc., Winooski, VT, USA) with Take3 microvolume
plate using Gen5 software. Subsequently, 1 μg of RNA was reverse transcribed into cDNA using
VILO Superscript reagent (11755050, Invitrogen) and cDNA was diluted to 1:100 (10 ng/μL).
Quantitative real-time PCR was performed using TaqMan probe reagent and QuantSudio3 PCR
instrument (ThermoFisher Scientific, Waltham, MA, USA), and Ct values were analyzed according
to the manufacturer’s instructions. PCR was as follows: 4-min of incubations, 45 cycles of
denaturation, annealing, and extension at 95 °C, 60 °C, and 72 °C, respectively. Target TaqMan
probes for β-actin (Mm00607939_g1), Cox4i1 (Mm01250094_m1), Igf1 (Mm00439560_m1),
Redd1 (Mm00512504_g1), Deptor (Mm01195339_m1), Ubc (Mm02525934_g1), Gadd45a
(Mm00432802_m1),

Atrogin1

(Mm00446190_m1),

Tnf

(Mm00458724_m1),

p62

(Mm01354484_m1),

MyoD

(Mm01278617_m1),

Pgc1α1

(Mm00499523_m1),
(Mm00443258_m1),

Murf1

(Mm01185221_m1),

IL-6

NF-κB

(Mm00476361_m1),

Lc3

(Mm01700766_M1),

Cyclin-D1

(Mm00432359_m1),

Pax7

(Mm01203489_g1),

Myogenin

(Mm00446194_m1),

Mki67

(Mm01208835_m1),

Pparγ

(Mm01184322_m1),

Nrf2

(Mm_00477784m1), Drp1 (Mm_00432881_m1), and Mtif2 (Mm00505356_m1) were purchased
from Applied Biosystems (Life Technologies). Additional custom primer pairs specific for Vdac,
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Pgc1α4, Beclin-1, Bnip3, Pparα, Tfam, OPA1, Mfn1, Mfn2, Mff, Fis1, TuFM, Taco1, and Mtif3
were used in which primer information has been reported previously (12, 81, 184). Final
quantification of mRNA level was calculated using the ΔΔCT method as described previously
(182, 184). All targets were normalized to the β-actin Ct value, which did not differ between
experimental groups.

xiii. Statistics
A one-way ANOVA with a factor of group was utilized as the global analysis for each
dependent variable. Where significant F-ratios were found, statistical differences among means
were determined by Tukey’s post hoc test. The comparison-wise error rate, α, was set at 0.05 for
all statistical tests. Only differences that reached significance by the global F test and significant
differences by Tukey-adjusted pairwise comparison are presented. All data were analyzed using
GraphPad Prism (La Jolla, CA, USA) and figures were compiled using GraphPad Prism as well.
Data expressed as mean ± Standard error of the mean (SEM).

E. RESULTS
i. Lower muscle and fat tissue weights with HT animals.
Tissue weights from all animals are presented in Table 1. In soleus muscle, HT had ~14%
and ~12% lower compared to PBS (p=0.003) and LT (p=0.024). In TA muscle, HT had ~12% and
~9% lower weights compared to PBS (p<0.001) and LT (p=0.017), respectively. In EDL and
plantaris muscles, no significant differences were observed. In addition, spleen weight, a
surrogate marker for the inflammatory state, was ~63% and ~296% greater in LT (p=0.010) and
HT (p<0.001) compared to PBS. Similarly, Liver weight was ~16% and ~32% greater in LT
(p=0.006) and HT (p<0.001) compared to PBS. Lung weight was ~19% greater in HT compared
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to PBS (p<0.001). Gonadal fat mass was ~34% and ~38% lower in 1 LT (p=0.030) and HT
(p=0.008) compared to PBS. Tumor weight was ~290% higher in HT compared to LT (p<0.001;
Table 1). These data suggest the HT group displayed mild cachexia compared to our prior male
CC study (12).

ii. Reduced female sex hormones with LLC injection.
Female sex hormone levels in plasma were assessed to determine hormonal changes
during CC. Both estrogen and progesterone levels in plasma had ~67% and 42% lower in 1 wk
following LLC injection, which remained suppressed in all tumor-bearing groups (p=0.05-0.038,
Table 1).

iii. Unchanged oxidative phenotype in tumor-bearing female mice
The mean percentage of SDH+ fibers in the plantaris muscle was not different among
experimental groups (p=0.350; Figure 1A-B). Moreover, fiber CSA distribution and mean fiber
CSA of both SDH+ and SDH- tended to be greater in the HT group compared to other groups
although statistically non-significant (p=0.089; Figure 1C-F). mRNA abundance of Vdac was ~4054% lower in HT compared to PBS (p<0.001), 1 wk (p=0.071), 2 wks (p=0.003), and LT (p=0.041;
Figure 1G) while protein contents of mitochondrial content (COX IV and VDAC) were not different
across the groups (supplemental figure 2A).

iv. Impaired skeletal muscle contractility with HT animals
In vivo isometric torque frequency data (unnormalized) demonstrated HT had ~77-121%
higher isometric torque during lower frequencies (10-60 Hz) than PBS (p=0.002-0.040; Figure
2A). Peak isometric torque (unnormalized) was not different between experimental groups
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(Figure 2B). Stimulation frequency at 50% peak torque was ~18% lower in HT compared to other
groups (p=0.001-0.013; Figure 2C). One-half relaxation time was ~71% slower in HT compared
to PBS (p=0.054; Figure 2D). Time to maximal contraction was ~127% slower in HT compared
to other experimental groups (p<0.001; Figure 2E). The fatigability test revealed no statistical
difference between PBS and LT or HT although 2 wks animals had ~12-42% greater fatigability
compared to 1 wk, LT, and HT at various time-points (10-30s and 60-70s; p=0.005-0.046; Figure
2F).

v. Inhibition of muscle protein anabolism
To determine protein synthetic function, we assessed 24 hours FSR determined by D 2O
labeling and cell signaling markers associated with protein synthesis. Mixed gastrocnemius
muscle FSR was ~40% lower in HT compared to PBS (p=0.043; Figure 3A) although there were
no statistical differences in TA (Supplemental Figure 3A). mRNA content of Pgc1α4 was ~62%
lower in 1 wk compared to LT (p=0.015) and insulin growth factor-1 (Igf1) was greater in 2 wks
compared to LT (~66%, p=0.009) and HT (~57%, p=0.016), respectively (Figure 3B). Redd1
mRNA content was ~17-fold greater in 1 wk compared to PBS (p=0.001), and ~3-6-fold greater
compared to 2 wks, LT, and HT (p=0.004-0.014, Figure 3C). Protein content of Deptor was
greater in LT compared to PBS (~3-fold; p=0.067) and 2 wks (~1.8-fold, p=0.012; Figure 3D)
while mRNA content of Deptor was ~45.1% greater in 2 wks compared to HT (p=0.046; Figure
3E).

vi. Atrophy-associated genes are upregulated with tumor development
We assessed mRNA content of genes from gastrocnemius within the UPS, autophagylysosomal pathway, and markers of inflammation to assess protein degradation systems during
the development of CC (Figure 4). First, mRNA content of Ubc (Ubiquitin C), Atrogin1, and Murf1
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were ~2.8-fold (p=0.019), ~3.5-fold (p<0.001), and ~4.5-fold (p=0.004) greater in HT compared
to other groups, respectively while Gadd45a demonstrated no difference from PBS (Figure 4A).
Regarding autophagy, the protein content of Beclin1 (a central marker for autophagy, initiating
autophagosome formation) was ~54% higher in 1 wk compared to PBS (p=0.021) and LC3 II/I
ratio (indication of autophagic activity) was ~190% higher in HT compared to 2 wks (p=0.038)
although there were no significant differences in total LC3 and p62 (a cargo protein that targets
other proteins that bind to it for selective autophagy) protein content (Figure 4B-C). On the other
hand, the mRNA content of Beclin1 was ~44% lower in HT compared to PBS (p=0.035) and Lc3
was ~39% higher in 2 wks compared to PBS and HT (p=0.019-0.040). No significant differences
in p62 content were observed (Figure 4D). Regarding inflammatory markers, IL-6 mRNA content
was ~90% greater in HT compared to other groups (p<0.001) and Tnfα was ~185% greater in 2
wks and LT compared to 1 wk (p=0.021-0.027; Figure 4E). There was no statistical difference
was found in NF-κB mRNA content (Figure 4E).

vii. Extrinsic regulators of skeletal muscle mass are altered during CC development
To examine extrinsic regulators of skeletal muscle mass, we assessed mRNA contents
from gastrocnemius for cell cycling and myogenesis. Cyclin-D1 (essential regulator of the G1-S
transition) was ~2.5-fold greater in 2 wks compared to other experimental groups (p<0.001).
Mki67 (cell proliferation marker) was ~2.5-fold greater in HT compared to PBS (~149%, p<0.001),
2 wks (~109%, p=0.002), and LT (~99%, p=0.003). Acta2 (a marker of myofibroblast) was ~57%
higher in 1 wk and 2 wks compared to PBS and HT (p=0.001; Figure 5A). Both Pax7 (the essential
regulator for muscle precursor cell proliferation) and MyoD (regulating both skeletal muscle
proliferation) were ~31-41% lower in HT compared to 1 and 2 wks p=0.001-0.045). No changes
were observed in Myogenin (muscle differentiation marker) mRNA content (Figure 5B).
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viii. Mitochondrial degeneration in HT
Histological assessment of MitoTimer (redox-sensitive reporter gene) data demonstrated
lower red to green ratio (oxidative stress) in 1 wk compared to LT (~27%, p=0.042) and HT (~30%,
p=0.009; Figure 6A and B). Greater pure red puncta numbers (completely degenerated
mitochondria) were observed in HT compared to PBS and 1 wk (~50%, p=0.005-0.022, Figure
6A and C). In addition, Mitochondrial respiratory function measured by the mitochondrial RCR
was ~49% higher in HT compared to PBS and 1 wk (p=0.021-0.036, Figure 6D) while mtROS
emission was not statistically different across experimental groups (Figure 6E).

ix. LLC impairs mitochondrial quality control and mitophagy in HT, but not in LT
Mitochondrial quality control was determined via assessing markers of mitochondrial
biogenesis, dynamics, translation initiation factors, and mitophagy from gastrocnemius. In
mitochondrial biogenesis, Pgc1α1 mRNA levels were ~44% lower in HT compared to PBS, 1 wk,
and 2wks (p=0.009-0.019; Figure 7A). Tfam mRNA levels were ~28% lower in HT and ~25%
lower in 1wk compared to PBS (p<0.001; Figure 7A). Nrf2 mRNA content was ~38% greater in
HT compared to PBS (p=0.026) and 1 wk (p=0.029) while there were no statistical differences in
Pparα or Pparδ (Figure 7A). In mitochondrial dynamics, Drp1 and Mff were higher in 2 wks and
lower in HT compared to PBS (~32%; p=0.024 and ~43%; p=0.002, respectively) while HT was
not different from PBS (Figure 7B). Mfn1 mRNA content was ~34% lower in HT compared to PBS
(p=0.014) while there were no statistical differences in Fis1 and OPA1 (Figure 7B). In
mitochondrial translation, TuFM, Taco1, and Mtif2 showed similar patterns that were gradually
elevated in 2 wks and reduced in HT (p=0.001-0.013) while no changes were observed in Mtif3
(Figure 7C). In mitophagy, both protein and mRNA content of BNIP3 was ~63% (p=0.010) and
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~147% (p<0.001) greater in HT compared to other groups, respectively (Figure 7D-E). There
were no statistical differences in protein contents for mitochondrial biogenesis and dynamics
(Supplemental Figure 2A, B, and D).

x. Antioxidant enzymes are unchanged during CC
The protein content of SODs -1, -2, and -3 and Catalase from gastrocnemius were not
statistically different among experimental groups (Supplemental figure 2C).

xi. Altered MAPK signaling in LT group
MAPK signaling from gastrocnemius was determined via assessing the phosphorylation
status of p38 and ERK. Although there were no statistical differences in protein content of pp38T180/Y182/p38, p-ERK1/2T202/Y204/ERK was ~7.3-fold higher in LT compared to PBS (p=0.034;
Supplemental figure 4A).

F. DISCUSSION
In this study, we aimed to assess alterations in the development of CC in LLC tumorbearing female mice. To do so, we assessed aspects of skeletal muscle contractile function and
metabolism including protein turnover and mitochondrial health. In addition, we observed a
distinct dichotomous effect in tissue wasting and cachectic phenotype within the 3 and 4 wk
animals where approximately half of the mice exhibited a relatively low tumor mass (<1.2 grams),
and the other half exhibited a substantially greater tumor mass (>2 grams). This was a particularly
interesting finding, as previous studies in male mice have shown gradual tumor development over
time following tumor implantation (12, 185). Furthermore, animals with HT exhibited higher protein
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degradation, impaired skeletal muscle contractility, and accelerated mitochondrial degeneration
while LT mice did not exhibit such cachectic phenotypes, despite up to 4 wks of tumor growth.
Our prior works have demonstrated impaired metabolic health in male mice prior to the onset of
cachexia itself (12, 81), compared to those works the current data suggest a relative protection of
muscle contractile and metabolic functions in female tumor-bearing mice in these earlier stages
of tumor development.
First, we observed a clear dichotomy in tumor burden among 3- and 4-wk tumor-bearing
female mice, wherein mice with higher tumor burdens developed a cachectic phenotype. This
dichotomy suggests a significant reliance upon tumor burden for the development of cancer
cachexia in female mice whereby timeframe of tumor development may not directly reflect
increases to tumor burden and corresponding cachectic phenotype. Considering, these effects
we regrouped 3- and 4- wk mice to low and high tumor bearing conditions to better reflect the
developmental process of cachexia in female mice. Our findings suggest LT mice may have a
protective mechanism to prevent cancer-induced cachectic phenotypes including tumor
development and muscle wasting although additional investigations are required to elucidate this
mechanism. Despite marked muscle loss in HT mice, this atrophy was less overt compared to
previous studies utilizing tumor-bearing male mice (12, 18). Specifically, females revealed ~314% overall muscle loss with significant muscle wasting in two muscles (TA and soleus) while
males underwent ~11-16% overall muscle loss with significant muscle wasting in four muscles
(gastrocnemius, TA, plantaris, and soleus muscle) out of five (12). Furthermore, CSA distribution
for oxidative and glycolytic muscle fibers as well as oxidative phenotype via SDH staining did not
differ between experimental groups although these markers were significantly lower in our
previous study using tumor-bearing male mice (12). These findings imply that while female HT
mice exhibit mild cachexia, female mice may have a protective effect on cancer-induced muscle
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wasting compared to male counterparts consistent with suggestions that females may be less
sensitive to inflammation-mediated muscle atrophies compared to males (45).
In addition to muscle wasting, impaired muscle contractile function is a strong indicator of
lower survival rate and impaired functional outcomes in advanced cancer patients (65). CC is
often associated with impaired muscle contractility including force production and fatigability (69).
Here, we observed impaired muscle contractility in HT mice, in agreement with findings from a
previous study (69). Indeed, we observed lower torque frequency at half maximum torque, slower
muscle contraction and relaxation times in HT mice, which was in line with prior works (186).
While speculative these data suggest preferential protection of slower twitch fibers in early phases
of cachexia itself, which aligns with preservation of oxidative fibers previously observed by our
group (12). Prior evidence also demonstrated decreased isometric muscle force production and
elevated muscle fatigue in male Apc Min/+ mice (colorectal cancer model) (69). However, another
study demonstrated unaltered fatigability in tumor-bearing female mice (187) as observed here
which may be associated with the relatively mild cachectic phenotype in our study. Collectively,
although fatigability may not be altered with early-stage CC, likely due to preferential survival of
slow-twitch fibers, muscle contractile function does still appear to be impaired with high tumor
development in female mice.
One of the major features of CC is the net loss of skeletal muscle protein as protein
degradation exceeds protein synthesis. Therefore, we assessed muscle protein anabolism and
catabolism across tumor development. In line with previous works (79, 81), we observed lower
muscle protein FSR in gastrocnemius of female mice with greater tumor burdens. We postulate
this is due to altered function of the protein anabolic system during the development of CC,
specifically the induction of anabolic/mTORC1 repressors, Deptor and Redd1, which were
observed greater prior to the onset of the cachectic phenotype (Figure 3C-D). We previously
observed a similar pattern in male tumor-bearing mice, whereby Deptor content was higher in
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pre-cachectic male mice (81), suggesting inductions of anabolic repressors precede cachexia and
may account for diminished protein synthetic rates as early-stage cachexia develops. It is
noteworthy to mention that although gastrocnemius FSR was lower in HT mice, this muscle mass
was intact. We speculate that unlike males, female gastrocnemius muscle mass appears to be
protected during the development of CC and may begin the wasting process at later stages of
cancer, which may not be enough to detect the significant muscle loss at the time of tissue
collection in the current study.
Protein degradation in skeletal muscle is largely mediated by two major processes, the
UPS and the autophagy-lysosomal pathway. Of note, we observe induction of E3 ligases,
Atrogin1 & Murf1, as well as UBC (10) in the HT mice (Figure 4A), in accordance with previous
male CC studies (35, 81). Moreover, we observed greater LC3II/I ratio in HT while p62 level did
not change, indicating an increase in autophagy initiation but not necessarily resolution in HT
mice. In addition, cancer-induced protein degradation is often associated with elevated
inflammation (15, 188) and inflammatory cytokines are well-known mediators of muscle wasting
during CC (35, 188, 189). The elevated IL-6 mRNA content observed in the HT group have also
been demonstrated previously in both clinical (189) and pre-clinical models of CC (15, 188).
Furthermore, these effects are of local induction of inflammatory cytokines at the level of the
muscle suggesting tumor-induced local inflammation in cachectic mice. Taken together, these
upregulated E3 ligases and proinflammatory cytokines appear to coincide and associate with
muscle wasting as well as tumor development in tumor-bearing female mice.
Adult skeletal muscle has a capacity to regenerate in response to proper stimuli (190) and
is often altered in various myopathologies including CC (81). Of note, previous evidence suggests
alteration to satellite cell function including the markers Pax7, Myogenin, MyoD, and Cyclin-D1 in
tumor-bearing male mice (81, 118). However, here we observed lower Pax7 and MyoD in only
the HT group (Figure 5B), suggesting a relative protection of myogenic regulators in females
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compared to previous male CC study (81). Further in-depth research on the cell cycle and
myogenic function is warranted to elucidate the regulation of muscle regeneration during CC,
especially within female mice.
Prior evidence demonstrates cancer-induced muscle mitochondrial degeneration
including diminished mitochondrial RCR, ATP production, and elevated mtROS emission (12, 18).
In addition, we have demonstrated these mitochondrial degenerations occur prior to muscle loss
in tumor-bearing male mice (12). Interestingly, here we report female mice exhibited unchanged
mtROS emission and greater mitochondrial RCR in HT, in direct contrast to lowered RCR in
cachectic male mice (12) and suggesting specific protection of mitochondrial health during cancer
cachexia in female mice. These data closely align with recent findings suggesting early
mitochondrial degeneration in male, but not female mice during disuse atrophy (11). Combined
data suggest a mechanism of mitochondrial degeneration to induce muscle atrophy is preserved
across pathologies specifically in male mice; yet in females these mitochondrial mechanisms may
be more nuanced in relation to muscle atrophy. Impaired mitochondrial function is often
associated with dysregulated mitochondrial autophagy (mitophagy) (12, 191), which contributes
to exacerbated mitochondrial degeneration. We observed induction of BNIP3 and an increase in
pMitoTimer pure red puncta in HT mice, reflecting the induction of mitophagy and accumulation
of damaged mitochondria in female mice upon onset of the cachectic phenotype (Figure 6-7).
While similar data are observed in male mice by our group (12) as well as others (192), in our
prior work these effects were observed well prior to onset of the cachectic phenotype in males in
contrast to later development in females. Further studies applying either pharmacological or
transgenic animal models of BNIP3 is warranted to determine its precise role in CC. Considering
data from the current study as well as other recent works (5, 183), we hypothesize that female
mice specifically protect mitochondrial health during myopathologies. This specific mitochondrial
protection may lead to attenuation of inflammatory forms of atrophy (i.e., CC) while prioritizing

81
mitochondrial health at the expense of muscle mass in non-inflammatory forms of atrophy (i.e.,
disuse).
Together with aforementioned mitophagy, mitochondrial quality control (MQC) is the
accumulation of systems required for maintaining mitochondrial integrity and function and is an
important defense mechanism for the cell’s survival from mitochondrial damage (121), often
altered in cancer (12). Herein, we observed altered mitochondrial biogenesis markers in HT mice.
Specifically, we found lower Pgc1α1 and Tfam, and greater Nrf2 contents in HT although these
effects were absent in previous male CC studies (12). In addition, some mitochondrial fission
markers (Drp1 and Mff) and translational factors (Taco1 and Mtif2) within females revealed a
similar pattern of elevation at 2 wks of tumor-bearing state, which may reflect mechanisms to
protect muscle mitochondrial health during early stages of tumor development. By contrast,
several of these mitochondrial biogenesis and dynamics markers were suppressed during the
development of CC in our previous male study (12) further exemplifying dichotomous effects
between biological sexes relative to maintenance of mitochondrial health during atrophic
pathologies.
Recent studies have addressed phenotypical differences between sexes in response to
different types of muscle atrophy such as those induced by disuse and cancer (45, 61, 170, 193),
with females possibly having exacerbated wasting compared to males in some myopathies such
as disuse, with the opposite being true in males and cancer. However, prior pre-clinical CC
studies have primarily focused on male animals, making it difficult to isolate the fundamental role
of biological sex during CC. Previously, Hetzler et al (64) demonstrated sex differences in IL-6
content in CC, whereby ApcMin/+ male mice had higher plasma IL-6 content than female
counterparts. However, to our knowledge, the current study is one of the first studies to
demonstrate various alterations in skeletal muscle during the initial development of CC in female
tumor-bearing mice. While some responses appear preserved between sexes, we observed
distinct differences in response to tumor development in females compared to prior male CC
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studies (12, 81). Specifically, both sexes exhibit impaired protein anabolism, upregulated E3
ligase-mediated protein degradation, and mitophagy in mice with greater tumor burden. However,
there were clear differences in oxidative phenotype, myogenic markers, MAPK signaling,
mitochondrial RCR, mtROS emission, and mitochondrial dynamics between sexes, wherein many
of these cellular alterations appear relatively protected in females while that of males was
significantly impaired prior to the onset of cachexia itself (12, 81). Among protected effects in
females compared to previous male studies, mitochondrial protection during the development of
CC appears to serve as a major contributor to preserve muscle mass although further
investigations regarding mitochondrial regulation in CC are warranted. Our findings suggest
distinct biological sex differences in development of CC and these differentially regulated
targets/pathways may be crucial in the protective mechanism in tissue wasting during CC in
females. Therefore, a critical need remains to directly investigate comparative alterations in the
skeletal muscle during the development of CC between males and females within a single study
using various cancer types to better delineate the role of biological sex in CC.
It is worth mentioning a limitation of this study is the use of younger mice (8 to 12 wks
old) to compare outcomes with prior works in male mice (12, 81, 194-196). However, with a
majority of human cancers are most prevalent in older adults (197). Therefore, future studies
should utilize aged animals to better recapitulate these clinical scenarios.
In conclusion, we set to investigate the initial development of CC in tumor-bearing female
mice revealing various metabolic and contractile impairments with tumor development.
Specifically, while many metabolic perturbations precede the onset of cachexia in males, female
tumor-bearing mice exhibit multiple protections in both metabolic and contractile functions in these
earlier stages of tumor development. These data suggest female mice may have a defense
system protecting them from tumor-induced muscle degeneration via maintaining muscle
regenerative processes, mitochondrial respiratory capacity, mitochondrial dynamics, and
oxidative capacity during the development of CC. Our data strongly imply females exhibit an
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enhanced capacity to mitigate aberrations associated with the onset of CC in the early stage of
tumor development. However, further works are necessary to delineate these specific protections
in female mice and their potential clinical utility.
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G. TABLES

Table 1. Characteristics
Tissue weights are recorded as wet weights. All tissue weights were normalized to their
tibia length to account for different body sizes. All values are represented as means ± SEM.
Different letters represent statistical differences at Tukey-adjusted with alpha value set at
p≤0.05. An N of 10-14 per group was used.
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H. FIGURES

Figure 1. Oxidative Phenotype
Plantaris muscle used for SDH staining. (A) SDH staining images are representative of
the five experimental groups. (B) Representative of the development of cancer cachexia through
% of SDH+ fibers. (C) Distribution through relative frequency (%) of cross-sectional area for SDH+
fibers and (D) SDH- fibers. (E) and Average cross-sectional area for SDH+ and (F) SDH- fibers.
(G) mRNA abundance for mitochondrial specific markers Cox4i1 and Vdac by utilizing the
Gastrocnemius muscle. Different letters represent statistical differences at Tukey-adjusted with
alpha value set at p≤0.05. An N of 4-9 per group was used.
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Figure 2. Skeletal Muscle Contractility
(A) Unnormalized isometric torque-frequency curve measured in mN·m for experimental
animal groups. (B) Unnormalized average peak torque (mN·m) across experimental groups. (C)
Frequency (Hz) delivered at 50% maximum torque across experimental groups. (D) Time (s) for
muscle to achieve half relaxation across experimental groups. (E) Time to maximal contraction
(s). (F) % peak torque measured over time (s) across experimental groups during fatiguing
protocol induced via continuous peroneal nerve stimulation. Different letters represent statistical
differences at Tukey-adjusted with alpha value set at p≤0.05. An N of 7-10 per group was used.
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Figure 3. Protein Synthesis
(A) 24 hours mixed muscle fractional synthesis rates (%/hr) across experimental groups.
(B) Pgc1α4 and Igf1 mRNA abundance measured among experimental groups. (C) Redd1 mRNA
abundance measured among experimental groups. (D) Protein content of Deptor relative to
Ponceau S among experimental groups. Both mRNA and protein contents were analyzed from
gastrocnemius muscle. Different letters represent statistical differences at Tukey-adjusted with
alpha value set at p≤0.05. An N of 9-14 per group was used.
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Figure 4. Protein Degradation & Inflammation
(A) Protein degradation measured by mRNA abundance for Ubc, Atrogin-1, Murf1 and
Gadd45a. (B) Protein content of autophagy-related markers; Beclin-1, LC3, LC3 II/I and p62
normalized to Ponceau S. (C) Representative immunoblot image for autophagy related markers
from the same membrane. (D) mRNA abundance of autophagy-related markers for Beclin-1, Lc3
and p62. (E) mRNA abundance of inflammation markers; IL-6, Tnfα and NF-κB. Both mRNA and
protein contents were analyzed from gastrocnemius muscle. Different letters represent statistical
differences at Tukey-adjusted with alpha value set at p≤0.05. An N of 10-14 per group was used.
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Figure 5. Myogenic & Cell Proliferation Factors
(A) Cell proliferation and (B) myogenic factors measured for mRNA abundance. (A) mRNA
abundance measured for Cyclin-D1, Mki67 and Acta2. (B) mRNA abundance measured for Pax7,
MyoD and Myogenin. mRNA contents were analyzed from gastrocnemius muscle. Different letters
represent statistical differences at Tukey-adjusted with alpha value set at p≤0.05. An N of 9-14
per group was used.
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Figure 6. Mitochondrial Function & Network
(A) Representative images of MitoTimer in the FDB muscle taken at 100x magnification.
Scale bar set at 100 µm. (B-C) Quantifications of MitoTimer in FDB muscle. (B) Quantification of
red to green ratio and (C) pure red puncta numbers quantified for MitoTimer. Pure red puncta are
representative of mitochondria that are marked for autophagy. (D-E) Mitochondrial function and
mtROS emission measurements of the plantaris muscle. (D) Respiratory Control Ratio (state 3:
state 4 respiration) and (E) H2O2 emission of mitochondria measured with permeabilized plantaris.
Different letters represent statistical differences at Tukey-adjusted with alpha value set at p≤0.05.
An N of 7-9 per group was used.
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Figure 7. Mitochondrial Quality Control
(A) mRNA abundance of mitochondrial biogenesis controllers for Pgc1α, Pparα, Pparẟ, Tfam
and Nrf2 among experimental groups. (B) mRNA abundance of mitochondrial dynamic controllers
for Drp1, Fis1, OPA1, Mfn1, and Mff among experimental groups. (C) mRNA abundance of
mitochondrial translation factors for TuFM, Taco1, Mtif2 and Mtif3 among experimental groups.
(D-E) Mitophagy regulator, BNIP3, measured for (D) mRNA abundance and (E) protein content
relative to Ponceau S with a representative image of immunoblot for Bnip3 and Ponceau S among
experimental groups. Both mRNA and protein contents were analyzed from gastrocnemius
muscle. Different letters represent statistical differences at Tukey-adjusted with alpha value set
at p≤0.05. An N of 10-14 per group was used.
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I.

SUPPLEMENTAL FIGURES

Supplemental Figure 1. Original and Regrouped Tumor Weights
(A) Original tumor weight distribution from 1 through 4 wks. (B) Regrouped animal
experimental groups within 3- and 4-wk animals based on their tumor weight. LT; low tumor and
HT; high tumor. An N of 10-14 per group was used.
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Supplemental Figure 2. Mitochondrial markers
(A-C) Quantification of immunoblots for mitochondrial quality controllers among
experimental groups. (A) Protein content for mitochondrial content and biogenesis controllers. (B)
Protein content for mitochondrial dynamics controllers. (C) Protein content for antioxidant
enzymes. (D) Representative image of immunoblot for mitochondrial quality controllers among
experimental groups. Both mRNA and protein contents were analyzed from gastrocnemius
muscle. An N of 10-14 per group was used.

94

Supplemental Figure 3. Protein Turnover
(A) TA muscle protein fractional synthesis rates (FSR) across experimental groups. (B)
Representative image and protein content of immunoblot for Ubiquitin relative to Ponceau S.
Protein content data was analyzed from gastrocnemius muscle. Different letters represent
statistical differences at Tukey-adjusted with alpha value set at p≤0.05. An N of 9-14 per group
was used.
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Supplemental Figure 4. MAPK Signaling
(A) Representative image and protein content of immunoblot for MAPK signaling specific
markers (p-p38, p38, p-ERK, and ERK). Phosphorylation site of both p38 and ERK was
normalized to their total protein content. Protein content data was analyzed from gastrocnemius
muscle. Different letters represent statistical differences at Tukey-adjusted with alpha value set
at p≤0.05. An N of 9-14 per group was used.
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CHAPTER IV: Manuscript from Specific Aim II

Targeting OPA1 for prevention of cancer-induced muscle loss.

Seongkyun Lim & Nicholas P. Greene
Formatted for Submission to Journal of Applied Physiology

A. ABSTRACT
Cancer Cachexia (CC) occurs in approximately 80% of cancer patients and is responsible
for 20-40% of cancer-related death although current therapeutic approaches lack sufficient
efficacy to prevent it. We previously demonstrated suppressed mitochondrial fusion protein, Optic
atrophy 1 (OPA1), during the early development of CC in male tumor-bearing mice. Moreover,
prior investigations revealed that loss of OPA1 is associated with lower muscle mass and impaired
muscle function. Conversely, overexpression of OPA1 ameliorated the phenotypes of
mitochondrial-associated diseases. However, the function of OPA1 as a therapeutic target in CC
has not been assessed. The purpose of current study was to elucidate the function of OPA1 in
CC using both pharmacological using BGP-15 (in vitro and in vivo) and genetic overexpression
of OPA1 (OPA1 TG) in vivo. For pharmacological in vitro experiments, C2C12 myotubes were
treated with Lewis Lung Carcinoma (LLC)-conditioned media (LCM) with or without BGP-15
(OPA1 drug target). BGP-15 was also administrated in LLC-induced tumor-bearing male mice to
determine regulation of muscle mass and function. For genetic overexpression experiments, we
utilized wildtype (WT) and OPA1 TG mice to further assess the efficacy of OPA1 in tumor-bearing
mice. Both BGP-15 in vitro and OPA1 TG in vivo experiments demonstrated attenuation of muscle
loss in response to LLC and LCM-induced CC. BGP-15 in vitro mRNA data further suggests the
protective effect on muscle wasting with BGP-15 treatment, which appears to be associated with
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suppressed inflammatory cytokine and autophagic-lysosomal pathway (ALP) activities mediated
via targeting OPA1. Our data suggests OPA1 as a potential therapeutic target for cancer-induced
muscle wasting.

KEYWORDS: Mitochondrial fusion, cancer cachexia, skeletal muscle, chemotherapy, and
atrophy.

NEW & NOTEWORTHY Our study demonstrates targeting of OPA1 utilizing both BGP-15
administration (in vivo & in vitro) and genetic overexpression (in vivo) were sufficient to attenuate
cancer-induced muscle wasting. Our data provide novel evidence that OPA1 may serve as a
potential therapeutic target for cancer-induced muscle wasting.
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B. INTRODUCTION
Cancer is the 1st or 2nd leading cause of death in more than 110 countries (19). There are
approximately 19.3 million new cases of cancer incidence and 9.9 million deaths annually (19).
More importantly, the number of new cases is anticipated to grow up to 28 million by 2040 (19).
Up to 80% of cancer patients undergo cancer cachexia, a wasting syndrome, which is clinically
defined as weight loss (mainly skeletal muscle and adipose tissue) more than 5% in the past 6
months (3). Skeletal muscle mass and function are considered important indicators for quality of
life and survival rate among cancer patients. A recent study demonstrated that recurring gastric
cancer patients with lower skeletal muscle mass were closely associated with lower survival rates
compared to gastric cancer patients with higher relative skeletal muscle mass (198). Along with
lower skeletal muscle mass and muscle function, impaired mitochondrial quality has been
implicated in both clinical and pre-clinical models of CC (12, 18, 69, 81, 199).
Mitochondrial quality is maintained by four major processes: mitochondrial biogenesis,
dynamics (mitochondrial fusion and fission), autophagy, and the mitochondrial permeability
transition pore (184, 200). Mitochondrial quality is the basis for maintaining the stability and
integrity of mitochondria and is an important defense mechanism against mitochondrial damage
(121). However, these mechanisms are often impaired during inflammation-induced diseases
including cancer (12, 18). White and coworkers (44) reported dysregulated mitochondrial
dynamics in a mouse model of CC. Mitochondrial dynamics are composed of two distinct
mechanisms, mitochondrial fusion and fission, the balance between these two determines
mitochondrial network health (121). Mitochondrial fusion occurs when two or more mitochondria
fuse/converse into one, forming constantly changing tubular organelles, leading to mitochondrial
elongation (121). Conversely, mitochondrial fission involves a mechanism by which a
mitochondrion pinches off the membrane to form daughter mitochondria (121). Cellular health
relies on a delicate balance between mitochondrial fusion and fission (145). Previous evidence

104
revealed higher fission proteins and lower fusion proteins in a mouse model of CC (44).
Interestingly, we found comparable results that tumor-bearing male mice revealed higher
mitochondrial fission and lower fusion protein content. Specifically, Optic atrophy 1 (OPA1), a
mitochondrial fusion marker, protein content was ~50% lower during the early development of CC
and this suppression was maintained into the development of marked atrophy (12).
OPA1 is enriched in the mitochondrial membrane and regulates the fusion of the inner
mitochondrial membrane and contributes to ATP synthesis and apoptosis (137-139). Loss of
OPA1 is associated with impaired skeletal muscle health including lower muscle mass and
function, leading to lower survival rates (166). In addition, OPA1 overexpression ameliorated the
phenotype of mitochondrial-associated disease mouse models (167). This prior evidence
suggests OPA1 plays a significant role in maintenance of skeletal muscle health and might serve
as a potential therapeutic target for skeletal muscle-associated diseases. However, the efficacy
of OPA1 as a therapeutic target in cancer-induced muscle atrophy has not been explored.
Therefore, the purpose of this study was to determine if pharmacological or genetic targeting of
OPA1 may attenuate cancer-induced skeletal muscle atrophy and degeneration including
impaired protein turnover, muscle contractile function, and mitochondrial quality utilizing both in
vivo and in vitro models of CC. To determine viability of utilizing currently available compounds to
attenuate CC via OPA1, BGP-15 was utilized. BGP-15 known as HSP-72 co-inducer (201) , has
recently been reported to promote OPA1 protein content (152), and has been demonstrated to
attenuate other forms of atrophy (202, 203). To more specifically test the function of OPA1 in CC
we utilized previously developed OPA1 transgenic mice which have been demonstrated to
attenuate a cachectic phenotype of mitochondrial-associated disease (167) . Herein, we
demonstrate in vitro BGP-15 treatment can attenuate cancer-induced atrophy, and while this
effect was absent in vivo BGP-15 administration experiment. However, transgenic overexpression
of OPA1 ameliorated LLC-induced muscle wasting.
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C. METHODS

I. Cell Culture Experiments
C2C12 murine myoblasts (CRL-1772, ATCC, Manassas, VA, USA) were plated in six-well
plates (5x104 cells/well) in 2 mL Dulbecco’s Modified Eagle Medium (DMEM; 11965092, Life
Technology, Carlsbad, CA, USA) combined with 10% Fetal Bovine Serum (FBS) and 1%
Penicillin/Streptomycin (P/S). Cells were incubated at 37°C with 5% CO 2 and media was changed
every 48 hours. Upon ~80% confluence, growth media was replaced with DMEM supplemented
with 2% horse serum, 1% P/S, 5% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES;
15-630-106, ThermoFisher Scientific, Waltham, MA, USA), 0.75% transferrin, and 0.75% insulin
for cell differentiation. C2C12 cells were differentiated for 5 days to become mature myotubes.
Cell proliferation and differentiation were performed as previously described (81, 204).

i. Lewis Lung Carcinoma Conditioned Media (LCM) and BGP-15 Drug Treatment
To collect LCM, Lewis Lung Carcinoma were grown up to 100% confluence as previously
described (81). LLC cells were then incubated in fresh DMEM supplemented with 10% FBS and
1% P/S for 24 hours. The media were then collected and centrifuged. The supernatant was
collected and diluted to 25% total volume of LLC media in serum free media (DMEM with 1%
P/S). For the control group 25% total volume of CCM (C2C12-conditiond media, prepared as per
LCM) was diluted in serum free media. Mature C2C12 myotubes were then treated with either
CCM or LCM for 72 hours. The media was changed every 24 hours as described (205). To assess
the efficacy of OPA1 in myotubes we treated myotubes either CCM or LCM with or without 10μM
of BGP-15 (OPA1 target). BGP-15 is primarily described as HSP-72 co-inducer and has been
described to promote OPA1 (152). Control cells were treated with same amount of dimethyl

106
sulfoxide (DMSO). Six replicates (wells) per condition was used and each condition was assessed
in two independent experiments (three replicates per each experiment).

ii. C2C12 Myotube Diameter
After myotubes were treated with either LCM or CCM with or without BGP-15 for 72 h,
myotubes were imaged with 10x and 40x objective with 5 images per well and 4-5 myotubes
examined per well.

iii. FSR in Cell Culture
FSR was assessed using gas chromatography-mass spectrometry (GC-MS) (7890 A and
5977 A, Agilent, Santa Clara, CA, USA) as described (81, 206). Briefly, 4% deuterium (D2O;
151882-1 L, Millipore Sigma, Burlington, MA) enrichment was diluted in 1.5 mL of culture media
in each 6-well plate 24 hours prior to cell harvest. Upon cell harvest, 6-well plate was washed with
PBS twice and added with 300 μL of 10% trichloroacetic acid (TCA) solution per well and cell
lysates were collected using cell scraper and transferred to 1.5 mL tubes. These lysates were
then homogenized for FSR. Mixed protein fractions were then washed three times with 10% TCA
solution by centrifugation to eliminate cytosolic amino acids. Proteins were then transferred in a
1.5 mL tube with 200 μL of 6 M HCl and heated at 100 C to hydrolyze proteins into amino acids
for 24 hours. An aliquot (50 μL) of the hydrolysate was dried down and derivatized with same
amount of 3:2:1 solution of methyl-8, methanol, and acetonitrile to determine 2H labeling of
alanine on its methyl-8 derivative. The derivatized solution was then placed in a GC-MS capillary
column (7890 A GC HP-5 ms capillary column, Agilent). 1 μL of the solution was run on the GCMS at a 20:1 split. A ratio of deuterated alanine over alanine was used to assess protein synthesis.
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The detailed method for FSR calculation was described in the methods for Chapter III and
elsewhere (81, 206).

iv. C2C12 RNA isolation, cDNA synthesis, and quantitative real-time PCR
After 72 hours of LCM intervention, the media was aspirated and washed with PBS. 1mL
of TRIzol reagent was added to each well in 6-well plate and cell lysates were then collected in a
1.5 mL microtube placed on ice. After 15-min at room temperature, 200 μL of chloroform was
added and samples were vortexed for 5-second and centrifuged for 25-min. After the
centrifugation, the clear portion of the solution from the top was placed into a new 1.5 mL
microtube. An equal amount of 70% of Diethyl Pyrocarbonate (DEPC) treated ethanol was added,
and the samples were loaded into a RNeasy column. RNA isolation was then processed using an
RNA isolation kit (K145002; Invitrogen, Carlsbad, CA, USA) per manufacturer protocol. A detailed
RNA isolation processes and RT-qPCR assessment were described in the methods for Chapter
III and prior study (206). Target TaqMan probes for 18s (Mm03928990_g1), IGF1
(Mm00439560_m1),

REDD1

(Mm00512504_g1),

DEPTOR

(Mm01195339_m1),

UBC

Atrogin1 (Mm00499523_m1),

Murf1

(Mm02525934_g1), GADD45a

(Mm00432802_m1),

(Mm01185221_m1),

FOXO1

(Mm00490671_m1),

(Mm00446190_m1),

TNF-α

(Mm00443258_m1),

NF-Κb1

(Mm00479807_m1),

LC3

(Mm00458724_m1),

p62

(Mm00432359_m1),

Pax7

(Mm01354484_m1),

MyoD

(Mm00446194_m1),

PGC1-α1

FOXO3

(Mm01208835_m1),

(Mm01185722_m1),

(Mm00476361_m1),

IL-6

NF-Κb2

(Mm01700766_M1),

Cyclin-D1

(Mm01203489_g1),

Myogenin

PPARγ

(Mm01184322_m1),

NRF2

(Mm_00477784m1), and DRP1 (Mm_00432881_m1) were purchased from Applied Biosystems
(Life Technologies). Additional custom primer pairs specific for ATG7, Beclin-1, Bnip3, PPARα,
TFAM, OPA1, MFN1, MFN2, MFF, FIS1, and OPA1 were used in which primer information has
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been reported previously (12, 81, 184). All targets were normalized to the 18s Ct value, which did
not differ between experimental groups.

II. Animal Interventions
Two separate sets of animal experiment were performed. 1) The first experiment was
designed to test the efficacy of BGP-15 to target OPA1 protein using mice treated with daily
administration of BGP-15 following tumor implantation, similar to in vitro experiments. 2) Second,
to more specifically determine if OPA1 promotion attenuates cancer-induced cachectic
phenotypes including muscle loss utilizing muscle OPA1 transgenic (TG) mice. By performing
these paired experiments, we were able to assess the specific function of OPA1 while also
providing whether pharmaceutical interventions with impacts on OPA1 may provide potential
therapeutic efficacy. All animal methods were approved by the Institutional Animal Care and Use
Committee of the University of Arkansas.
Experiment 1) 33 male C57BL/6J mice were purchased from Jackson Laboratory (000664,
Bar Harbor, ME, USA) and divided into 4 different experimental groups (7-9 mice per group),
(Con-PBS, Con-BGP-15, LLC-PBS, & LLC-BGP-15), (Con: control, PBS: phosphate-buffered
saline, & LLC: Lewis lung carcinoma). Con-BGP-15 and LLC-BGP-15 animals were given a daily
administration of BGP-15 (20mg/K BW) at 8 wks of age for 21 days while control animals were
given a daily administration of PBS.
Experiment 2) 21 male (16 OPA1 TG and 5 WT) mice (C57BL/6J background) were
divided into 4 groups (WT-PBS, WT-BGP-15, OPA1-PBS, & OPA1-BGP-15). OPA1 TG mice
were developed by Dr. Luca Scorrano (U. Padova) and initial OPA1 TG breeders were provided
by Dr. Thomas Sanderson (U. Michigan) via Dr. Luca Scorrano (U. Padova) and the breeding
colony was maintained at our animal facility.
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All experimental mice were kept on a 12:12-h light-dark cycle, housed at 72 degrees
Fahrenheit, and given ad libitum access to normal rodent chow and water for the duration of the
study. At 8 wks of age, experimental mice from both studies were subcutaneously given an
injection of either LLC cells (1 x 10 5/side) suspended in 100 μL sterile (PBS) or an equal volume
of sterile PBS as a sham control to both right and left hind flank. Tumors were allowed to develop
for up to 3 to 4 wks. 5 muscle (soleus, plantaris, gastrocnemius, TA, and EDL) and 5 non-muscle
tissues (heart, liver, spleen, tumor, and gonadal fat) were collected and tissue wet weight was
measured. Plasma was separated from the blood by centrifugation. Tissue and plasma samples
were then snap-frozen in liquid nitrogen and stored at -80 °C for further analysis. All tissue weights
were normalized to their initial bodyweight to account for different body mass prior to the LLC
implantation.

i. Lewis Lung Carcinoma Cell Culture
LLC cells (CRL-1642, ATCC, Manassas, VA, USA) were plated in a 250 mL cell culture
flask in 10% growth media with 1% penicillin/streptomycin and media was changed every 48
hours. Upon ~80% confluence, cells were trypsinized, suspended, and diluted in PBS prior to LLC
implantation as described in the methods for Chapter III and prior study (12).

ii. Plasmid DNA Amplification and Electroporation
pMitoTimer plasmid were amplified and plasmid DNA were isolated using PureLink HiPure
Plasmid Filter Maxiprep kit (K211017, Life Technologies) as per manufacturer protocol. At 6 wks
of age, pMitoTimer plasmid were transfected into the right flexor digitorum brevis (FDB) muscle.
More detailed protocols for pMitoTimer transfection were described in the methods for Chapter III
and elsewhere (12, 204).
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iii. In vivo Muscle Contractility Test
Approximately 48 hours prior to tissue collection, in vivo peak isometric torque, isometric
torque frequencies, frequency at half maximum torque, 1/2 relaxation time, time to maximal
contraction, and fatigability (susceptibility to fatigue) of the anterior crural (shin) muscles were
performed as described (161). Briefly, while mice were anesthetized, the left hindlimb was shaved
and an ethanol pad applied to clean the skin. The foot was placed in a footplate attached to a
servomotor (Model 300B-LR, Aurora Scientific, Aurora, Ontario, Canada) using surgical tape
while their body temperature was maintained at 37 °C using a heating pad. Two platinum
electrodes (Model E2–12, Grass Technologies, RI, USA) were then inserted percutaneously on
either side of the peroneal nerve. Muscle contractions were induced via electrical stimulator and
stimulus isolation unit (Model S48 and SIU5, respectively; Grass Technologies). Torque and Mwave as a function of stimulation frequency were measured during 12 isometric contractions with
the duration of 150 ms at various stimulation frequencies (10, 20, 30, 40, 60, 80, 100, 125, 150,
200, 250, and 300 Hz) to determine hindlimb motor unit recruitment based on two different
physiological conditions: 1) hindlimb motor unit recruitments during normal movement, which
occurs between 60 and 100 Hz(178). 2) During supra-maximal stimulation frequencies (i.e., >200
Hz) can reveal different contractile phenotypes such as low-frequency fatigue (179) followed by
resting the hindlimb for 4-min. After measurement of submaximal and maximal isometric torques
at 150 Hz, the anterior crural muscles underwent a fatigability test via applying 120 isometric
contractions with duration of 150 ms per each stimulation at 40 Hz for a total protocol time of 2 min. During the recovery following the fatigability test, the normal movement of experimental mice
was closely monitored to determine any injuries during the in vivo muscle force production and
fatigability test.
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iv. Fluorescence Microscopy for pMitoTimer
pMitoTimer was analyzed as previously described (12). Briefly, at the time of tissue
harvesting, freshly collected FDB muscles were fixed with 4% paraformaldehyde (PFA) for 20min followed by 5-min incubation with PBS at room temperature. Muscles were then spread out
on a gelatin-coated glass slide using 2 forceps and mounted with a drop of 50% glycerol in PBS
as mounting media. A coverslip was added on the top of the mounted sample and 4 drops of nail
polish were applied at the corners to anchor the coverslip. pMitoTimer images were acquired at
x100 magnification using the FITC (green; excitation/emission, 488/518 nm) and TRITC (red;
excitation/emission, 543/572 nm) fluorescent channels on a Nikon Eclipse Ti-S inverted epifluorescent microscope (Nikon, Melville, NY, USA) with LED-based light source. Standardized
acquisition parameters were established and followed for all imaging to match across samples.
All assessments were performed in congruence with Laker et al. (163). A specially generated
MATLAB program, a generous gift from Dr. Zhen Yan (U. Virginia), was used to analyze
pMitoTimer red to green ratio (a mitochondrial oxidative stress marker) and pure red puncta
number (a marker for completely degenerated mitochondria) (163).

v. Preparation of Separated and Permeabilized Muscle Fibers
During tissue harvesting, ~15 mg of fresh plantaris and gastrocnemius muscles were
collected and placed in a petri dish containing ice-cold buffer X (60 mM K-MES, 35 mM KCl, 7.23
mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM taurine, 5.7 mM ATP,
15 mM phosphocreatine, and 6.56 mM MgCl2 at pH 7.1). Connective tissues and blood clots were
eliminated, and the fiber bundles were gently separated into a near-single fiber bundle to
maximize their surface area under an upright stereoscopic microscope (Fisher Scientific,
Waltham, MA, USA) using a pair of extra-sharp forceps (Fisher Scientific). The finely separated
fiber bundles were then permeabilized in a tube with saponin (50 μg/mL) on a rotator for 30-min
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at 4 °C. The permeabilized fiber bundles were washed in ice-cold buffer Z (110 mM K-MES, 35
mM KCl, 1 mM EGTA, 5 mM K2HPO4, 3 mM MgCl2, 0.005 mM glutamate, 0.02 mM malate, and
0.5 mg/ml BSA at pH 7.1) for 5-min x 3 times as previously described (12, 181). The permeabilized
fiber bundles were then used for mitochondrial RCR (12).

vi. Mitochondrial Respiratory Control Ratio (RCR)
Mitochondrial oxygen consumption was measured by polarography in a respiration
chamber maintained at 37 °C (Oxygraph+, Hansatech Instruments, King’s Lynn, UK) as described
(12) and this method was adapted from Min et al (181). Briefly, permeabilized plantaris muscles
were transferred to a respiratory chamber filled with 1 mL of respiration buffer Z containing
creatine (20 mM) to saturate creatine kinase and allowed to equilibrate with the tissue for 5- to
10-min before adding any substrate. State 2 respiration was assessed by the addition of malate
and pyruvate (5mM) using 10 μL 701RN Syringes (Hamilton, Reno, NV, USA) followed by
maximal ADP-stimulated respiration (State 3) by adding ADP (0.25 Mm) and then basal
mitochondrial respiration (State 4) by the addition of oligomycin (10 μg/mL) to inhibit ATP
synthesis. The respiratory control ratio (RCR) was calculated by dividing State 3 by State 4
respiration.

vii. Statistics
For cell experiments, a two-way ANOVA was used as the global analysis for each
dependent variable. Independent variables were Media condition (CCM versus LCM) and drug
condition (dimethyl sulfoxide (DMSO) versus BGP-15). For animal experiments, a two-way
ANOVA was utilized. Independent variables within each sex included genotype (WT vs. OPA1
TG) and injection type (LLC vs. PBS). When significant F ratios were found, statistical differences
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among means were determined by Tukey’s post hoc test. The comparison-wise error rate, a, was
set at P < 0.05 for all statistical tests. All two-way ANOVA data and figures were analyzed using
GraphPad Prism (La Jolla, CA). Data were expressed as means ± standard error (SEM).
Footnote: All figures can be found at the end of chapter IV.
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D. RESULTS

i. BGP-15 attenuates LCM-induced myotube atrophy.
To determine the efficacy of BGP-15 on myotube size during muscle cell atrophy in
response to LCM, we treated myotubes with or without BGP-15. We found an interaction effect
on myotube diameter. Specifically, myotubes treated with LCM-CON and LCM-BGP-15 were
smaller in LCM-CON (~16%; p<0.001) and LCM-BGP-15 (~9%; p=0.002) compared to CCMCON. Although LCM-CON myotubes were~12% smaller than CCM-BGP-15 (p<0.001), no
statistical differences were found between CCM-BGP-15 and LCM-BGP-15. Myotubes treated
with LCM-CON were ~7% smaller than LCM-BGP-15 (p=0.028; Figure 1A-B).
To determine protein synthesis, we assessed FSR via 24 hrs of D 2O labeling. Although
there was no main effect of LLC on FSR due to smaller sample size in LCM-CON, FSR was ~25%
lower in myotubes treated with LLC (Figure 1C). FSR of LCM-CON was ~5.3-fold lower than
LCM-BGP-15 (Figure 1C). To further assess regulation of the protein anabolic system, mRNA
level of anabolic suppressors (DEPTOR and REDD1) and regulating factors (Insulin like growth
factor1 [IGF]) were assessed. An interaction effect on REDD1 was observed, where REDD1
mRNA content was ~28% (p=0.041) and ~53% (p<0.001) higher in CCM-BGP-15 compared to
LCM-CON and LCM-BGP-15, respectively (Figure 1D). There are no further statistical differences
found in DDPTOR and IGF1 mRNA level (Figure 1E-F).

ii. Suppressed autophagic-lysosomal pathway (ALP) and inflammatory cytokine mRNA in
myotubes treated with BGP-15.
To determine alterations to protein degradation systems, we first examined mRNA content
for ubiquitin-proteasome system (UPS). Although E3 ubiquitin ligases, Atrogin, and MuRF were
unchanged among experimental groups, Ubiquitin C (UBC) revealed an interaction effect.
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Specifically, UBC mRNA level was ~77% higher in CCM-BGP-15 compared with CCM-CON
(p=0.029; Figure 2A-C). To further assess upstream targets for E3 ligases, we assessed FOXO1
and FOXO3. While no changes were found in FOXO1, there was an interaction effect on FOXO3
mRNA content, which was greater in CCM-BGP-15 (~51%; p=0.011) and LCM-CON (~44%;
p=0.031) compared with CCM-CON (Figure 2D-E). As protein degradation was mainly driven by
APS and ALP, we assessed mRNA content for ALP-related genes including ATG7, p62, LC3, and
Beclin. A main effect of BGP-15 was noted on ATG7, with BGP-15 treated myotube exhibiting
~57% lower ATG7 mRNA content compared with CON myotubes (p=0.014; Figure 2F). We found
an interaction effect of p62. Specifically, p62 mRNA level was ~37% greater in LLC-CON
compared with CCM-CON (p=0.028) while this effect was absent between CCM-CON and LLCBGP-15 (Figure 2G). There are no statistical differences in LC3 and Beclin, although Beclin was
~49% higher in BGP-15 than CON (p=0.066; Figure 2H-I).
Since inflammatory cytokines play a crucial role in CC, we assessed mRNA content for
pro-inflammatory cytokines (IL-6 & TNF-α) and NF-kB. We found a main effect of LCM on IL-6,
where IL-6 was ~7.7-fold greater in LCM-treated myotubes compared to CCM control (p=002;
Figure 2J). A main effect of BGP-15 noted on TNF-α level that the BGP-15 group was ~73%
lower in TNF-α compared with CON myotubes (p=0.038). We did not find any statistical
differences in NF-kB2 mRNA content (Figure 2L).

iii. Greater OPA1 and compensatory regulation of mitochondrial quality control mRNA levels in
response to BGP-15 treatment in myotubes.
Considering that BGP-15 is an upstream target for OPA1, which is a mitochondrial fusion
protein, we sought to assess mitochondrial dynamics markers (mitochondrial fusion and fission)
at the mRNA level. A main effect of LLC was noted on mitochondrial fission 1 (FIS1) that FIS1
mRNA level was ~42% lower in both LCM treated myotubes compared to CCM treated (p<0.001;

116
Figure 3A). Although not statistically significant, DRP1 was ~45% lower in LCM-BGP-15
compared with CCM-BGP-15 (p=0.063; Figure 3B). No statistical significance was found in MFF.
A main effect of BGP-15 was noted on OPA1, with BGP-15 treated myotubes showing ~64%
greater OPA1 mRNA content compared with CON myotubes (p=0.046; Figure 3D). No significant
difference was found in other mitochondrial fusion markers including MFN1/2 (Figure 3E-F).
To determine mitochondrial biogenesis, we assessed mRNA content for PGC1α1, PPARγ,
TFAM, and NRF2. We found a main effect of LCM on PGC1-α1, with LCM treated myotubes were
~84% higher in PGC1-α1 levels compared with CCM treated myotubes (Figure 3G). We did not
find any statistical significance in other mitochondrial biogenesis markers including PPARγ,
TFAM, and NRF2 (Figure 3H-J) BNIP3 as a mitophagy marker revealed a main effect of LCM,
with LCM treated myotubes were ~53% lower in BNIP3 mRNA content compared with CCM
myotubes (Figure 3K).

iv. Unchanged cell cycling and myogenic regulators in response to LCM or BGP-15 treated
myotubes.
To determine changes in cell cycling and myogenic regulators in response do LCM with
or without BGP-15, we assessed mRNA content for Pax7, MyoD, Myogenin, and cyclin D1.
Although we did not find any statistical significance in those markers, the mean mRNA contents
for Pax7, MyoD, and Myogenin were ~42%, ~51%, ~44% lower in BGP-15 treated myotubes
compared with CON myotubes, respectively (Figure 4A-D).

v. Potential role of BGP-15 in CC in vivo.
Tissue weights from all animals are presented in Figure 5. Tissue weights for different
skeletal muscles and non-skeletal muscles were measured to determine the efficacy of BGP-15
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in response to LLC-induced tumor development. We found a main effect of LLC on tumor-free
bodyweight that LLC mice were ~12% lower in tumor-free bodyweight compared with CON mice
(p=0.008; Figure 5A). In skeletal muscle tissues, we found a main effect of LLC on soleus,
plantaris, and gastrocnemius muscles. Specifically, muscle tissue weights of LLC mice were
~13% (soleus; p=0.018), ~9.7% (plantaris; p=0.049), and ~13% (Gastrocnemius; p=0.023) lower
compared with CON mice, respectively (Figure5 A, B, & E). An additional main effect of LLC was
noted in non-skeletal muscle tissues, with LLC mice having ~13% lower heart (p<0.001), ~31%
lower gonadal fat (p=0.009), and ~1.9-fold higher spleen tissue weights (p=<0.001), respectively
(Figure 5H, I, & K). There are no statistical differences in bodyweight, EDL, TA, liver, and tumor
weights among experimental groups (Figure 5).

vi. Impaired muscle contractile function in LLC-induced tumor-bearing mice, but no protective
effect with BGP-15 administration.
To determine muscle contractile function, we performed an in vivo electro-physiology test
to assess torque frequencies, fatigability, peak torque force, time to maximal contraction, halfrelaxation time, and Hz at 50% maximal contraction. We found an interaction effect on torque
frequencies, with CON-PBS mice having ~45-57% greater torque at lower frequencies (from 30
to 60 Hz) compared with CON-BGP-15 and LLC-PBS mice (p<0.05; Figure 6A). There was a
main effect of LLC on fatigability that the fatigability of LLC mice, where the fatigability of LLC
mice was ~12-20% lower from 40 to 70 stimulations compared with CON animals (p<0.05; Figure
6B). We did not find statistical differences in peak torque, time to maximal contraction, halfrelaxation time, and Hz at 50% maximal contraction among experimental groups (Figure 6C-F).
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vii. Mitochondrial degeneration induced by LLC was attenuated by BGP-15 administration.
To determine mitochondrial network health, we assessed computational analysis of
MitoTimer fluorescence. Although we did not find any statistical differences in MitoTimer red to
green ratio (measurement for oxidative stress), we found a main effect of BGP-15 in pure red
puncta (marker for complete mitochondrial degeneration due to mitophagy), with BGP-15 mice
having ~71% lower pure red puncta level compared with PBS animals (Figure 7A-C).

viii. LLC induced muscle wasting was ameliorated by OPA1 overexpression in vivo (OPA1 TG).
Tissue weights from all animals are presented in Figure 8. At 8 wks of age, we found a
significant difference in initial bodyweight (before the intervention) between WT and OPA1 TG
animals, where OPA1 TG animals were ~5% lower compared to WT counterparts (p=0.028;
Figure 8L). Therefore, tissue weight data were normalized to their initial BW prior to the LLC or
PBS administration. We found a main effect of LLC with multiple tissues, with tumor-bearing mice
having lower tumor-free body weight (~5%; p=0.022), gastrocnemius muscle (~7%; p=0.009),
EDL muscle (~18%; p=0.06), and greater spleen tissue weight (~1.4-fold; p=0.014) compared
with PBS animals (Figure 8A, C, F, K). A main effect of TG was found across multiple muscles,
with OPA1 TG mice having higher soleus (~14%; p=0.015), gastrocnemius (~10%; p=0.008),
plantaris (~%, p=0.044), EDL (~28%; p=0.017), and heart (~17%; p=0.017) weights relative to
initial BW compared to WT animals (Figure 8B-C, E-F, I). There were no additional statistical
differences in other tissue weights (TA, liver, fat, and tumor weight; Figure 8D, G, H, J).

ix. Unchanged muscle contractile function in OPA1 TG mice.
To further determine skeletal muscle contractile function mouse in vivo muscle electrophysiology was performed for torque frequency curve, peak isometric torque, fatigability, time to
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maximal contraction, and time to half-relaxation. Although there were no statistical differences in
torque frequencies and peak torque among experimental groups (Figure 9A & C), we found an
interaction effect on multiple points of fatigability, with OPA1 TG-PBS animals showing ~6-26%
greater torque at 10-40th stimulations compared to other animal groups (p<0.05; Figure 9B).
There was an interaction effect on time to maximal contraction, with WT-PBS mice having ~1.1fold faster time to maximal contraction compared to other groups (p=0.013, Figure 9D). No
additional statistical differences were found in half-relaxation time and Hz at 50% maximal
contraction (Figure 9E-F).

x. Unchanged mitochondrial network health & function in OPA1 TG mice.
Mitochondrial network health was assessed via computational analysis of MitoTimer
fluorescence. We did not find any statistical differences in MitoTimer red to green ratio or pure
red puncta although mean pure red puncta counts were ~53% higher in WT-LLC mice compared
with OPA1-LLC (Figure 10A-C).
To determine mitochondrial respiratory capacity RCR was measured. We did not find any
statistical differences on RCR among experimental groups (Figure 10D-E).
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E. DISCUSSION
In the current study, we sought to determine if targeting OPA1 may attenuate cancerinduced muscle wasting by utilizing both pharmacological (both in vivo and in vitro) and a genetic
overexpression model (in vivo). To our knowledge, this is one of the first studies to test the function
of OPA1 in CC. We demonstrated both pharmacological and genetic overexpression of OPA1induced a protective effect on muscle wasting. Our mRNA data from BGP-15 in vitro experiments
revealed a protective effect on inflammatory and autophagy systems in myotubes treated with
LCM plus BGP-15. This may suggest a potential mechanism of how OPA1 plays a role in cancerinduced muscle wasting. OPA1 TG in vivo experiments also resulted in an attenuation of muscle
wasting in OPA1 overexpressed animals in response to LLC-induced cachexia. However, BGP15 was largely ineffective as an in vivo approach to attenuate CC suggesting, therefore further
experiments are necessary to identify translational therapeutic strategies that may target OPA1
to attenuate CC. Findings from BGP-15 in vitro and OPA1 TG in vivo experiments suggest OPA1
as a potential target to mitigate cancer-induced muscle wasting.
First, we set to test the efficacy of BGP-15, a pharmacological inducer of inducible HSP72,
recently reported to promote OPA1 protein content (152), to alleviate cachexia in vitro. We treated
differentiated myotubes with LCM to induce CC. LCM resulted in a smaller myotube diameter
compared with the CCM control group, which was attenuated with BGP-15 intervention. This was
partially supported by our protein synthesis data via FSR using 24 hrs of the D2O labeling method.
Lower protein synthesis in myotubes treated with LCM was normalized by BGP-15 although it did
not reach a statistical significance. Previous studies reported 5 days of BGP-15 administration in
a rodent intensive care unit (ICU) model resulted in attenuation of soleus muscle loss (203).
Another study showed that 10 days of BGP-15 treatment after a muscle injury was able to
ameliorate muscle atrophy (202). In addition, Campelj and coworkers (207) demonstrated that
chemotherapy (irinotecan)-induced muscle atrophy was normalized by BGP-15 administration.
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These prior investigations including the current study suggest BGP-15 may serve as a potential
therapeutic target for various muscle atrophic conditions.
To further determine potential molecular mechanisms involved in muscle mass regulation
in response to BGP-15 in vitro, we assessed various cellular signaling markers and pathways at
the mRNA level via RT-qPCR. First, we found elevated mRNA content of OPA1 in myotubes
treated following BGP-15 intervention, indicating the BGP-15 treatment in vitro was sufficient to
promote OPA1 mRNA content. Our mRNA data shows that some of the cellular signaling markers
including inflammation and autophagy associated targets along with OPA1 appear to be involved
in preventing muscle loss in LCM-mediated CC in vitro. Various pro-inflammatory cytokines such
as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) have long been known to play an
essential role in CC (9, 208, 209). These pro-inflammatory cytokines are often elevated in
inflammation-mediated diseases including cancer, altering various cellular pathways associated
with weight loss, especially skeletal muscle and adipose tissue weights via increasing protein
degradation systems and lipolysis (9, 81). In line with the prior evidence, we found elevated IL-6
and TNF-α mRNA content in LCM-induced myotubes. Interestingly, the TNF-α level remained low
when myotubes were treated with BGP-15, suggesting BGP-15 might have an effect to inactivate
TNF-α, thereby interfering protein degradation system in CC.
Protein degradation is mainly driven by two distinct mechanisms, the UPS and ALP, which
are often activated during different forms of muscle atrophic conditions including cancer (12, 206)
and disuse (10, 11). Our data revealed that UPS-associated mRNA markers such as ubiquitin E3
ligases (Atrogin and MuRF) and FOXO1 remained unchanged. However, we found interesting
changes in ALP-related markers. Specifically, autophagy-related 7 (ATG7), an important gene
essential for autophagy and cytoplasmic to vacuole transport (210), remained low in BGP-15
treated myotubes. In addition, sequestosome-1 (p62), an autophagosome cargo protein that
targets other proteins for selective autophagy (211), was higher in LCM treated myotubes
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compared with CCM control, which was normalized by BGP-15 treatment. Taken together, these
observations from our in vitro experiments suggest promotion of OPA1 via BGP-15
overexpression appears to be associated with lowering inflammatory cytokine and ALP activities,
thereby attenuating muscle loss in response to CC in vitro.
Activation of pro-inflammatory cytokines is one of the hallmarks of CC, which has been
implicated with dysregulation of the mitochondrial quality control (MQC) system including
mitochondrial biogenesis and dynamics (fusion and fission) (12, 18). OPA1 regulates the fusion
of the inner mitochondrial membrane and contributes to maintaining mitochondrial integrity (212).
Previous studies demonstrated depletion of OPA1 dysregulated genes associated with
mitochondrial dynamics and biogenesis (212). Furthermore, Civiletto and coworkers (167)
demonstrated that overexpression of OPA1 ameliorated phenotypes of mitochondrial-associated
diseases such as muscle wasting and impaired mitochondrial function in mice. In the current
study, BGP-15 intervention in vitro induced greater OPA1 mRNA content both in CCM and LCM
treated myotubes. Although we did not find any main effect of BGP-15 in mitochondrial fission
and biogenesis markers, we observed a compensatory main effect of LLC in mitochondrial fission
and biogenesis. Specifically, we found upregulation of PGC-1α and downregulation of FIS1 and
BNIP3. Previous investigations demonstrated that these three MQC-related markers are often
dysregulated in response to CC in the opposite direction (downregulation of PGC-1α and
upregulation of FIS1 and BNIP3) (12, 18, 44, 206) from what we observed in the current study.
This might suggest a compensatory mechanism of mitochondrial fission and biogenesis in
response to LCM-induced CC in vitro. Further investigations are warranted to determine protein
content of these markers to determine more precise regulations of MQC in LCM-induced CC.
Based on observations from this in vitro study, we sought to test the function and role of
OPA1 in a mouse model of CC using both pharmacological (BGP-15 administration) and skeletal
muscle-specific genetic overexpression of OPA1. In the current study, we used LLC-induced
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tumor-bearing mice as an animal model of CC. This model has been well studied by our group
(12, 81, 206) and others (194, 213, 214) and validated to induce cachectic phenotypes including
marked muscle loss within 4 wks following tumor implantation (194, 206). In line with prior studies,
both animal studies induced marked skeletal muscle loss in response to LLC allograft. For the
BGP-15 in vivo experiments, mice administered with BGP-15 did not exhibit any protective effects
on muscle tissue weights, which was not corresponding to previous studies utilizing BGP-15
treatment in atrophic rodents (202, 203, 207). The discrepancy between prior studies and the
current study was that while we used an IP injection of BGP-15 (20mg/kg) for 21 days, others
utilized either a higher dose (40mg/kg) (203) or a different method of delivery (oral gavage) (202).
Most importantly, while others utilized a mechanically ventilated rat ICU (203) or chemotherapyinduced cachectic mouse model (207), we used a tumor-bearing mouse model. It is likely the
tumor allograft presented with confounding effects of BGP-15 on the tumor which must be
accounted for in pharmacologic approaches to treat CC. To our knowledge, we are the first to test
the efficacy of BGP-15 in tumor-bearing mice.
In addition to a loss of muscle mass, impaired skeletal muscle function is prevalent in CC
such as lower muscle contractility and accelerated muscle fatigue in both animals (68, 69) and
humans (65). In the current study, tumor-bearing mice exhibited exacerbated muscle fatigability
although BGP-15 treatment did not impact fatigability. Furthermore, lower torque frequencies
were present in LLC-PBS mice compared with CON-PBS group, which appeared partially
attenuated by BGP-15 treatment at low stimulation frequencies. Muscle contractility can be
governed by various contractile unites such as fiber type, motor unit, ATPase activity, and
neuromuscular connection (67, 215). Since BGP-15 did not affect muscle mass in tumor-bearing
mice, the partial correction of torque frequencies in LLC-BGP-15 mice may have been driven by
preserved contractile units in the development of CC.
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Since mitochondrial quality is often dysregulated in various models of muscle atrophy (12,
18, 206), we assessed computational analysis of MitoTimer fluorescence to determine
mitochondrial network health. We found greater MitoTimer pure red puncta in the LLC-PBS group,
which was normalized by LLC-BGP-15 treatment, indicating LLC-induced mitochondrial
degeneration appears to be partially attenuated with BGP-15 administration. MitoTimer pure red
puncta is considered as an indicator for mitochondria targeted for removal from the cell via
mitophagy (163). We have previously reported elevation of MitoTimer pure red puncta and
mitophagy level such as BNIP3 in tumor-bearing mice (12, 206). Therefore, it is plausible
attenuation of pure red puncta level in LLC-BGP-15 mice was partially mediated by decreased
mitophagy activity in CC although the underlying mechanism is still unclear. Hence, further studies
are required to test the function of BGP-15 in the comprehensive aspects of mitochondrial
degeneration in CC.
We originally hypothesized that BGP-15 would induce protective effects on muscle
wasting via targeting OPA1 in tumor-bearing mice. However, muscle atrophy induced by tumor
development was not attenuated with BGP-15 administration. These findings were not matched
with our BGP-15 in vitro data, which suggests BGP-15 action in vivo might be confounded by
tumor presence. Accordingly, to more specifically test the role of OPA1 in CC, we utilized skeletal
muscle-specific overexpression of OPA1 in tumor-bearing mice. Interestingly, LLC-induced
muscle wasting including gastrocnemius and EDL was attenuated with OPA1 overexpression
while the tumor mass was unchanged compared with WT-LLC mice. A prior study showed that
COX15 deficient mice (mitochondrial disease model) exhibited smaller muscle cross-sectional
area (CSA) and impaired mitochondrial function, however, these negative effects were normalized
by OPA1 overexpression (167). Evidence from the current study and others therefore suggests
OPA1 may play an essential role in regulating different forms of muscle atrophy.
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To further determine if OPA1 overexpression can induce protective effects on common
cachectic phenotypes including impaired muscle contractile function and mitochondrial network
health in response to tumor development, we applied the same assessments performed for the
BGP-15 in vivo experiments. We did not find any changes in muscle torque frequency or peak
isometric torque among the experimental groups. In fatigability measurement, however, we found
greater fatigability in OPA1-PBS mice than in other groups while this effect was absent in OPA1LLC group. Furthermore, mean torque frequency was slightly lower in OPA1-LLC mice compared
with other groups. It is worth mentioning one of the limitations of this study that the number of
mice in OPA1 TG groups was 2 to 3 per group, while WT animals were 7 to 8 per group. There
was relatively high variability between two mice in that OPA1-LLC group, resulting in a lower
mean torque frequency with relatively higher SEM. Since this study is still ongoing, these muscle
contractility data might be different from the current data once we have sufficient power for these
assessments. At the end of the current OPA1 TG project, we are expected to have 10-12 mice
per each group.
In conclusion, we sought to determine the function of OPA1 utilizing both a
pharmacological induction (both in vitro and in vivo) and genetic overexpression of OPA1 method
(in vivo). Both BGP-15 in vitro and OPA1 TG in vivo experiements resulted in attenuation of
muscle loss in response to LLC and LCM intervention, suggesting the potential efficacy of
targeting OPA1 in CC. However, in vivo data with treatment by BGP-15 do not suggest a likely
use of BGP-15 as a viable therapeutic for CC and thus a need remains to discover viable options
to target OPA1 during CC. BGP-15 in vitro mRNA data suggests that a protective effect on muscle
wasting via BGP-15 treatment appears to be associated with lower inflammatory cytokine as well
as ALP activities potentially mediated by OPA1 upregulation. Although the OPA1 TG in vivo
experiment is still ongoing, the current data provides a promising therapeutic potential for cancerinduced muscle wasting.
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F. FIGURES

Figure 1. BGP-15 attenuates LCM-induced myotube atrophy
(A-B) Measurement and representative images of myotube diameter in response to
LCM/CCM with or without BGP-15. (C) Protein synthesis rate via FSR using 24 hours of D 2O
incorporation. (D-E) mRNA abundance of protein anabolic suppressors (DEPTOR and REDD1)
and (F) anabolic regulating factor; Insulin like growth factor1 (IGF1). An N of 5-6 replicates (wells)
per condition was used and each condition were tested in two independent experiments (3
replicates per each experiment). Only one sample was detectable for FSR in LCM-CON group
due to a low FSR abundance in panel C.
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Figure 2. Suppressed APL and inflammatory cytokine mRNA in myotubes treated with BGP-15.
(A-E) mRNA abundance of UPS related markers; Atrogin, MuRF, UBC, FOXO1, &
FOXO3. (F-I) mRNA abundance of APL related markers; ATG7, p62, LC3, Beclin. (J-L) mRNA
abundance of inflammatory cytokines; IL-6, TNF-α, & NF-kB. Data described as mean ± SE.
Statistical significance identified by denoting as * for main effect of LLC or BGP-15, and as
“different letters” for an interaction effect with alpha value set at p<0.05. ME: Main effect. An N of
5-6 replicates (wells) per condition was used and each condition were tested in two independent
experiments (3 replicates per each experiment).
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Figure 3. Greater OPA1 and compensatory regulation of mitochondrial quality control mRNA
levels in response to BGP-15 treatment in myotubes.
(A-B) mRNA abundance of mitochondrial fission markers; FIS1 & DRP1. (C-F) mRNA
abundance of mitochondrial fusion markers; MFF, OPA1, MFN1, & MFN2. (G-J) mRNA
abundance of mitochondrial biogenesis markers; PGC-1α, PPARγ, TFAM, & NRF2. (K) mRNA
abundance of mitochondrial autophagy marker; BNIP3. Data described as mean ± SE. Statistical
significance identified by denoting as * for main effect of LLC or BGP-15 with alpha value set at
p<0.05. ME: Main effect. An N of 5-6 replicates (wells) per condition was used and each condition
were tested in two independent experiments (3 replicates per each experiment).
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Figure 4. Unchanged cell cycling and myogenic regulators in response to LCM or BGP-15
treated myotubes.
(A-C) mRNA abundance of myogenic regulating factors; PAX7, MYOD, & Myogenin. (D)
mRNA abundance of cell cycling marker; Cyclin D1. An N of 5-6 replicates (wells) per condition
was used and each condition were tested in two independent experiments (3 replicates per each
experiment).
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Figure 5. Potential role of BGP-15 in CC in vivo.
(A) Tissue weight measurement for tumor-free bodyweight. (B-F) Tissue weight
measurement for lower limb muscles; Soleus, Gastrocnemius, TA, Plantaris, and EDL. (G-K)
Tissue weight measurement for non-muscle tissues; tumor, gonadal fat, heart, liver, and spleen.
(L) Tibia length measurement. Data described as mean ± SE. Statistical significance identified by
denoting as * for main effect of LLC or BGP-15 with alpha value set at p<0.05. ME: Main effect.
An N of 5-9 animals per group was used.
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Figure 6. Impaired muscle contractile function in LLC-induced tumor-bearing mice, but no
protective effect with BGP-15 administration.
(A) Torque frequency curve measured in mN-m. (B) Fatigability measurement shows
percent decrease in peak torque (mN-m) following 120 E-simulations in 120 seconds at 40 Hz.
(C) Peak isometric torque (mN-m) (D) Time to maximal contraction. (E) Half relaxation time (F)
Hz at half maximal contraction. Data described as mean ± SE. Statistical significance identified
by denoting as * for main effect of LLC or BGP-15, and an interaction effect with alpha value set
at p<0.05. ME: Main effect. An N of 5-9 animals per group was used.
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Figure 7. Mitochondrial degeneration induced by LLC was attenuated by BGP-15 administration.
(A) MitoTimer Red to Green Ratio (B) MitoTimer Pure Red Puncta counts. (C)
Representative images of MitoTimer in single muscle fiber. Data described as mean ± SE.
Statistical significance identified by denoting as * for main effect of BGP-15 with alpha value set
at p<0.05. ME: Main effect. An N of 2-7 animals per group was used.
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Figure 8. LLC induced muscle wasting was ameliorated by OPA1 overexpression in vivo (OPA1
TG).
(A) Tissue weight measurement for tumor-free bodyweight. (B-F) Tissue weight
measurement for lower limb muscles; Soleus, Gastrocnemius, TA, Plantaris, and EDL. (G-K)
Tissue weight measurement for non-muscle tissues; tumor, gonadal fat, heart, liver, and spleen.
(L) Tissue weight measurement for initial bodyweight. All tissue weight data were normalized to
their initial bodyweight to account different body mass prior to the experimental intervention. Data
described as mean ± SE. Statistical significance identified by denoting as * for main effect of LLC
or BGP-15 with alpha value set at p<0.05. ME: Main effect. An N of 2-8 animals per group was
used.
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Figure 9. Unchanged mitochondrial network health & function in OPA1 TG mice.
(A) Torque frequency curve measured in mN-m. (B) Fatigability measurement shows
percent decrease in peak torque (mN-m) following 120 E-simulations in 120 seconds at 40 Hz.
(C) Peak isometric torque (mN-m) (D) Time to maximal contraction. (E) Half relaxation time (F)
Hz at half maximal contraction. Data described as mean ± SE. Statistical significance identified
by denoting as * for an interaction effect with alpha value set at p<0.05. An N of 2-8 animals per
group was used.
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Figure 10. Unchanged mitochondrial network health & function in OPA1 TG mice.
(A) MitoTimer Red to Green Ratio (B) MitoTimer Pure Red Puncta counts. (C)
Representative images of MitoTimer in single muscle fiber. (D) Plantaris mitochondrial respiratory
capacity via RCR. (E) Gastrocnemius mitochondrial respiratory capacity via RCR. An N of 2-7
animals per group was used.
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I. CONCLUSION
A. CHAPTER 3: Development of metabolic and contractile alterations in development of
cancer cachexia in female tumor-bearing mice.
In this study, we set to investigate alterations in the skeletal muscle during the
development of CC focused on tissue weights, protein turnover, mitochondrial quality, and muscle
contraction. We found carious metabolic and contractile impairments with tumor development.
However, these alterations are relatively minor and protected compared with previously reported
male studies. The current study imply that females exhibit an enhanced capacity of mitigate
aberrations associated with the onset of CC in the initial stages of tumor development. Further
works are necessary to delineate these specific protections in female mice to provide precise
mechanisms.

B. CHAPTER 4: Targeting OPA1 for prevention of cancer-induced muscle loss.
In the second study, we set to test the function of OPA1 utilizing both BGP-15
administration (in vivo & in vitro) and genetic overexpression of OPA1 (in vivo) in CC. Both BGP15 in vitro and OPA1 TG in vivo studies resulted in protective effects on muscle wasting in
response to LCM and LLC-induced CC. BGP-15 in vitro data further suggests that the protective
effect on muscle loss in CC appears to be associated with decreased inflammation and ALP
activity. Further works are required to fully understand the efficacy of OPA1 in CC.

C. Overall Conclusion.
This dissertation tested two independent but related research hypotheses. First, we
investigated molecular alterations in the skeletal muscle during the development of CC in females.
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These data demonstrated impaired metabolic and contractile function as tumor develops.
However, these metabolic and contractile dysregulations are relatively modest compared to that
of males from previous studies (12, 81), suggesting a distinct biological sex differences in the
development of CC. Second, targeting OPA1 via both in vivo and in vitro resulted in protective
effects on muscle wasting and regulations of both inflammation and ALP appear to be involved in
muscle mass regulation during CC, suggesting OPA1 could be potential therapeutic target for
cancer-induced muscle wasting.
Overall, my dissertation studies suggest both biological sex and mitochondrial health are
crucial aspects when it comes to cancer-induced muscle atrophy. Especially, OPA1 plays a
crucial role in mitochondrial homeostasis and females have a greater protective effect on
mitochondria degeneration than males in response to CC, it would be invaluable to investigate
the role of OPA1 in females during the development of CC. These two major findings from the
current dissertation studies would provide as invaluable information in the field of cancer research
and can help to advance the therapeutic potential for clinical cancer patients.
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D. Limitations and Delimitations
i. Limitations
There are a few limitations inherent to these studies. Limitations of Aim 1 (Chapter III)
were relatively minimal compared to Aim 2 (Chapter IV) in that Aim 1 was completed and
successfully published in Journal of Applied Physiology on January 5th, 2022. During the
submission process, I was able to minimize limitations and improve the quality of article. However,
there were a few limitations for Aim 1. Specifically, our tumor allograft method was utilized in
relatively young mice (8 to 12 wks old). These mice were considered as young adult compared to
human development. However, according to National Cancer Institute’s Surveillance,
Epidemiology, and End Results (SEER) from 2013-2017, the median age of human cancer
diagnosis is 66 years old, which is considered as older adults. For that reason, our animal model
of CC may not accurately represent that of human cancers. Thus, future studies should consider
utilization of more aged animals to better represent the nature of human cancer patients. In
addition, we used LLC allograft as an animal clinical model of CC. Although these carcinomas
were derived from the lung, the tumors do not arise in the tumor tissue of origin. This might be
another limitation of the current study in that this off-site tumor development may not properly
represent the type of tumor. Therefore, future works are warranted to utilize more transplantable
models to better represent the type of cancer/tumor.
Regarding limitations for Aim 2, there were a few limitations that are worth mentioning.
For the OPA1 TG study, data presented in the current dissertation is not complete. Here, we have
used 21 male mice which is nearly half of the final animal numbers in males. Therefore, we could
not process tissue samples for more analysis such as protein and mRNA signaling,
immunohistochemistry, and mitochondrial reactive oxygen species emission rate by the time of
my dissertation defense. In addition, I was going to have both males and females to investigate
biological sex differences with OPA1 in vivo experiments. However, due to the lack of numbers
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per each group in females (one mouse in both WT-PBS and WT-LLC group) by the time of
dissertation defense, elected not present female data in the current dissertation as current data
are insufficient to draw conclusion. Therefore, data from OPA1 TG experiments to date are more
representative of pilot data.

ii. Delimitations
For Aim 1 study, we elected to investigate alterations in the skeletal muscle of females to
determine potential biological sex differences in CC. Although this may limit the nature of
biological sex investigation without including males in the current study, the study design was
matched to our prior male CC studies (12, 81) to more directly compared alterations between
males and females. We opted to utilize LLC allograft as a pre-clinical model of CC for both Aim 1
and 2 studies. However, the interpretations may be limited when we deliver general messages
from the current studies in that our LLC model is derived from lung tissue, which represents lung
cancer. Accordingly, our findings may or may not well represent other types of cancer. However,
the current study was specifically designed to follow and investigate further finding from previous
works (12, 81). In this case, our study design and model would provide more strength of this
study.
For Aim 2 study, we had to opt to use a transgenic animal model of OPA1 study to test
the efficacy of OPA1 instead of a AAV-induced intra-muscular gene transfer method that I
proposed originally. OPA1 study was strengthened by utilizing more direct approach to test the
function of OPA1. Although AAV model have a high efficiency rate of gene transfer, transgenic
models will have more strength in this study in that this system induces overexpression of OPA1
gene in the skeletal muscle more efficiently.
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E. Final Thoughts
My dissertation data provides two novel research outcomes that 1) biological sex as an
important variable in the development of CC & 2) Mitochondrial fusion protein OPA1 as a potential
therapeutic target for cancer-induced muscle degenerations. More detailed mechanisms of how
females are protected during the development of CC and more precise roles of OPA1 in CC are
warranted to advance cancer therapy, thereby improving cancer outcomes.
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B. Protocols
I. Cachexia Research Laboratory – Analysis of protein synthesis via FSR in vitro.
A detailed method was described in the methods for Chapter III and IV and this section
will be committed for the analysis of FSR using muscle samples from in vitro. After the
completion of FSR measurement, it is required to assess both plasma and tissue calculated
enrichment to determine the final FSR value.

i. Sample analysis (for both plasma and tissue)
1. Open the MS Quantitative Analysis software from the desktop.
2. File > New Batch (Or open batch for existing batch) > Select Samples/Standards to be
included in batch processing.
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3.

Selecting OK will load all selected samples/standards into the batch processing screen.

4. Method > Open > Open and Apply from Existing File.
5. Select 2H-Acetone or 2H-Alanine in the C:\GCMS\inch\daMethods directory.
6. Analyze the entire batch by selecting Analyze > Analyze Batch. Or by pressing F5.
7. Every sample/standard will be listed in a drop-down box.

8.
9. The samples can be navigated by selecting a sample from the drop-down box, or by
pressing the green arrows to the left or right of the drop-down box.
10. Each sample reports the retention time (RT), Response, Height, and Area (Response
and Area are the same) for all isotopes measured by the GCMS method that was used
during data acquisition. For 2H-Alanine, this is m/z 99 and 100. For 2H-Acetone, this is
m/z 58 and 59. For each, the heavier isotope corresponds to deuterium enrichment.
Each isotope can be selected by clicking on the appropriate name in the table. For the
purposes of this protocol, each parent ion (99 and 58) will be referred to as m+0, and
each labeled molecule (100 and 59) will be referred to as m+1.
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11. Below this window there are two larger windows:
a. Sample Information: shows the extracted chromatogram for each isotope being
measured).
b. Compound Information: shows a focused chromatogram for the isotope selected
in step 9.
12. The analysis software has attempted to measure the peak height and area under the curve
using various algorithms. Visually inspect each chromatographic peak for appropriate
software integration and adjust where appropriate. See end of document for examples of
inappropriate peak shapes and their common causes and possible solutions.

13. Errors in automatic peak integration are indicated with various colors that correspond to
various problems. The above picture on the right is an example of bad peak integration.
This is due to the jagged nature of the peak causing the software to be unsure if this is a
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single peak, or two almost overlapping peaks. In this case, manual integration must be
performed to fix the problem.
14. Begin manual integration by selection the manual integration icon in the “Compound
Information”

window.

Then, for this particular integration problem, select “Merge Right Peak.” The resulting peak
should

now

be

integrated

properly

and

appear

similar

to

other

peaks.

15. Once all peaks for each isotope have appropriate integrations, it will be necessary to reanalyze the batch by selecting “Analyze > Analyze Batch” or by pressing F5.
16. To export all data, select “Report > Generate” from the toolbar. The following menu will
appear.

The default path to save the report is the same folder where the samples are saved. The
report method for both 2H-Alanine and 2H-Acetone is FSR-Report. Clicking “OK” will begin
generating a data output report in a new excel spreadsheet. The folder containing this new
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spreadsheet will open automatically when the report is generated. This can take a few
seconds, to a few minutes depending on how many samples are included in the batch
report.
17. This Excel spreadsheet will contain a list of samples with their retention times, peak height,
and area under the curve for each isotope measured.
18. By taking the ratio of m+1/m+0 area under the curve for each sample, we can then
compare them to a standard curve linear equation.
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ii. Plasma calculated enrichment.
1. For plasma samples, graph the response of plasma standards using a scatter plot with
percent enrichment on the y-axis and the m+1/m+0 ratio on the x-axis. Calculate a bestfit line equation and R2. The R2 should be above 0.99 if done correctly. Apply each plasma
sample to the best fit line as the x variable, and y will be plasma enrichment for that
sample.

2. Apply equation from the scatter plot e.g., = (21.196*K63)-0.7816 to 58/59 value = final
plasma enrichment.
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iii. Muscle tissue calculated enrichment.
1. For tissue samples, we use the separate excel spreadsheet found in the “GCMS
Standards” folder on the GCMS computer. Follow the instructions within the spreadsheet
on the worksheet titled “STD 1-6 Linear”.

2. When it is exported to excel, get ratio of 99/100 area value “see red circled”. Open an
excel file “STD 2020 Corr Area” and go to a tab named as “STD 1-6 Linear”
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3. Copy and paste your m+0, m+1, and 99/100 values from your working excel to “STD 1-6
Linear” tab. locate your mouse cursor at first sample under “m+0” (in the example, it is cell
“B13”). Then hit “control + Y” This will automatically get you R 2 and calculated enrichment
(CE) values. Copy R2 and CE values and transfer back to your working excel sheet.
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4. Copy R2 and CE values and transfer back to your original excel file. Get a mean of each
sample (each sample was triplicated) (see red circled). Note: you can exclude one of your
triplicates if one values is too lower or higher than the other two.

5. Reorganize based on animal group and number. Normalize your tissue CE to Plasma CE
value to get a final FSR value. Note: You should have plasma CE data in different excel
file at this point. Transfer plasma CE to here for the final FSR value.

